

17th World Conference “Esophagus 2026”

Versailles | June 14-17, 2026

Palais des Congrès

Under the presidency of

W.W. Chan (USA)
Gastroenterology

A. Hölscher (Germany)
Surgery

M. Moehler (Germany)
Oncology

Congress Secretaries

E.M. Stein (USA)
Gastroenterology

R.P. Tatum (USA)
Surgery

Scientific Committee Presidents

J.O. Clarke (USA)
Gastroenterology

P. Grimminger (Germany)
Surgery

C. Scarpignato (Italy)
Pharmacology

D.H. Wang (USA)
Oncology

Scientific Program

Accreditation:
16.5 EACCME®
CME credits.

www.oeso.org

Foreword

The number of diseases of the esophagus is high

- **Gastro-Esophageal Reflux Disease (GERD)**, prevalence: 15% of the population of North America
 - Frequent evolution to **Barrett's esophagus**, risk factor for
 - **Esophageal cancer** increasing death rates, 500,000 cancer deaths each year
 - Esophageal and foregut motility disorders,
 - Eosinophilic esophagitis,
 - Food and foreign body impactions,
 - Caustic injuries,
 - Complex esophageal and foregut disorders,
 - Esophageal ruptures and perforations,
 - Neonatal stenoses,
- ... Esophagology has become a **science**, poly-disciplinary in its essence.

Cooperation with

- UNESCO (2 Chairs in Telemedicine) ,
- New York Academy of Sciences,
- ... and, since 2018,
an active association with Stanford Medicine



United Nations
Educational, Scientific and
Cultural Organization



Stanford
MEDICINE

SEMPIRE

Stanford Esophageal Multidisciplinary
Program in Innovative Research Excellence

(About OESO

The World Organization for Specialized Studies on Diseases of the Esophagus (OESO) was founded in 1978 by Professor Robert Giuli. From its inception, OESO has been unique in bringing together professionals from **19 different disciplines**, all focusing exclusively on the esophagus. Today, OESO encompasses gastroenterologists, endoscopists, surgeons, oncologists, radiologists, pathologists, speech therapists, nutritionists, and researchers, creating a truly multidisciplinary global platform.

OESO has more than 10,000 corresponding members across 85+ countries. It has organized landmark congresses, published the multi-volume OESO Encyclopedia of Esophagology, and created the SEMPIRE Platform of Excellence in Esophagology for global education and collaborative research.

OESO's mission is to foster innovation in clinical care, stimulate pioneering research, and promote knowledge-sharing to advance esophageal health worldwide.

19 different disciplines

Gastroenterology

Surgery

Motility

Robotics

Endoscopy

Pediatrics

Immuno-genetics Biotechnology

Radiology-Endosonography

Physiology

Epidemiology

Pathology

Oncology

Endoscopic Surgery

Oto-Laryngology Speech Language – Deglutology

Pharmacology

Molecular Biology

Biochemistry

Health Economics

Biomechanics



Robert Giuli

Professor of Surgery

Founder & Deputy Executive Director of OESO

Coordination of programs

The OESO-SEMPIRE Scientific Program

The scientific program is based on sessions of 90 minutes (1h30).

A new, original format will be applied to 15 "Chat sessions":

- *At the start of these sessions, an informal 10-minute chat between the two chairs will enable them to introduce the questions to follow, explain their design, and discuss their terms. This free conversation on the stage will allow the audience to grasp the reasons behind the choice of the questions that were considered to best shed light on the topic of the session.*
- *Six questions will follow, according to the OESO format, with answers given in 5 minutes by a speaker considered as an expert in the domain.*
- *After 30 minutes and 6 answers given to these questions, the speakers will join the chairs on stage, to take part in an intense 50-minute discussion between themselves and with the audience, to wind up the session.*



In addition of **the pre-congress course on Motility** and poster / abstract sessions, almost half of the scientific program (15 sessions) is based on this model, but with 2 different types of sessions:

- **7 sessions** will apply the format in 90 minutes: Sessions 7-16-20-23-26-29-32
- **4 grand sessions**, with broader subjects, will apply it over two consecutive sessions (3h): Sessions 2-5, 8-11, 14-17, 21-24.

Furthermore,

- **18 sessions** will comprise traditional presentations of 6 minutes each, followed by 3 minutes of discussion: Sessions 1-3-4-6-9-10-12-13-15-18-19-22-25-27-28-30-31-33

With **180 traditional presentations, 90 answers to high level scientific questions and 270 speakers**, the program of the congress will therefore deliver to the scientific community a message that will be an exceptional synthesis with, in addition, presentations of all selected abstracts.

It will correspond in the best possible way to the title of Congress:


"Esophagus 2026"

	OESO-SEMPIRE 17 th World Conference “Esophagus 2022”			
	Auditorium Lulli		Auditorium Richelieu	
DAY 1 SUNDAY, JUNE 14				
01:00 pm – 05:00 pm	Course on Motility (coffee break 15 min)			
5:30 pm			OPENING CEREMONY	
DAY 2 MONDAY, JUNE 15				
09:00 am – 10:30 am coffee break 30 min.	1	Oncology: Multimodal Therapy	2	Functional Disorders – From Bariatric to Diaphragm and Back
11:00 am – 12:30 pm	4	Distinguished Abstracts Plenary – Clinical Research	5	Functional Disorders – Talking to the Past: Rome in Versailles
12:45 pm – 01:45 pm	Lunch Symposium A sponsored by AstraZeneca Navigating Gastroesophageal Cancer Care: a Case-based Discussion.		Lunch – Time for networking – Mazarin Hall	
02:00 pm – 03:30 pm coffee break 30 min.	7	Laryngopharyngeal Reflux Disease (LPRD): Cutting Through the Noise	8	Robotic Surgery
04:00 pm – 05:30 pm	10	Pilot Centers	11	Robotic Surgery
05:30 pm – 06:30 pm				
6:30 pm	SOCIAL PROGRAM			
DAY 3 TUESDAY, JUNE 16				
09:00 am – 10:30 am coffee break 30 min.	13	GI Clinical Pharmacology & Therapeutics	14	Esophageal Cancer – Best Surgical Treatment for Esophageal Adenocarcinoma
11:00 am – 12:30 pm	16	AI and Digital Technology in Esophagology	17	Esophageal Cancer – Special Approaches for Treatment of Squamous Cell Carcinoma
12:45 pm – 01:45 pm	Lunch Symposium B sponsored by MSD Redefining Care in Unresectable and Metastatic Esophageal Cancer: The Role of Multimodal Treatment Approaches.		Lunch – Time for networking – Mazarin Hall	
02:00 pm – 03:30 pm coffee break 30 min.	19	Surgical Endoscopy: Pushing the Envelope of What Can Be Done with the Endoscope	20	Eosinophilic Esophagitis – Hot Topics & Unanswered Questions
04:00 pm – 05:30 pm	22	Oncology – Palliative Treatment Options	23	GERD – When Standard Therapy Fails
7:30 pm	GALA EVENING at the Grand Royal Stables of the Palace of Versailles. Dress code: Black Tie.			
DAY 4 WEDNESDAY, JUNE 17				
09:00 am – 10:30 am coffee break 30 min.	25	Esophageal Motility Disorders: Controversies and Challenges (this or that)	26	State of the Art Surgery
11:00 am – 12:30 pm	28	Obesity and the Esophagus	29	Barrett’s Esophagus: Management and Prevention
12:30 pm – 01:45 pm	Lunch – Time for networking – Mazarin Hall			
02:00 pm – 03:30 pm	31	GERD: Nuts and Bolts	32	Challenging Cases in Surgery
03:30 pm – 05:00 pm	CLOSING OF THE CONFERENCE			


6" Versailles June 14-17, 2026			
ieu	Auditorium Condé		Room Montesquieu
M O N Y			
rain	3	Distinguished Abstracts Plenary – Basic and Translational Science	
	6	Therapeutic Endoscopy: New Frontiers	
orking	Lunch Forum <i>(by invitation only)</i> OESO Esophageal Motility and Reflux Trainee Forum – Room Boileau		Lunch Symposium D <i>sponsored by MIMEDX</i> Human Placental Allografts as a Protective Barrier After Complex Esophageal Anastomoses in High-Comorbidity Patients.
	9	KCHUGR-OESO Joint Session on Global Perspectives in Advanced Endoscopic Techniques	
	12	Eosinophilic Esophagitis: State of the Art	
			Poster Session in the Mazarin Hall (Poster exhibition area)
A M			
gical enocarcinoma	15	Techniques and Tips in Esophageal Practice: GERD, Antireflux Surgery, and Esophageal Cancer	Dynamic Imaging: Case Training for Multilevel Dysphagia "Deglutology meets Esophagology"
aspects ell Esophageal	18	KSNM-OESO Joint Session: Esophagology – East vs West	
orking	Lunch Symposium C <i>sponsored by inno.N</i> Tegoprazan: New Clinical Evidence and Expanding Therapeutic Perspective.		
t Topics	21	Dynamic Imaging 1 – Dynamic Esophagology Morphology	
py Fails	24	Dynamic Imaging 2 – Functional Disorders	
essage performance by the Equestrian Academy of Versailles.			
	27	Barrett's Esophagus: Physiology & Diagnosis	
ment	30	Esophageal Pathology: Key Controversies and Updates	
Mazarin Hall			
	33	Challenging Cases in Oncology	
O N G R E S S			

Go to

the OESO-SEMPIRE
17th World Conference
Program at a glance
Website with the
following QR Code



Go to
the OESO-SEMPIRE
17th World Conference
Program at a glance
Website with the
following QR Code



DAY 1

Sunday, June 14

Program

DAY 1 Sunday, June 14

Motility Course

Sunday, June 14, 1:00 – 5:00 pm
■ Auditorium Lulli

I. Indications and Protocols for Esophageal Function Testing

Chairs: **Walter W. Chan (USA)** – **Ellen Stein (USA)**

1. What are the indications for esophageal manometry? – **Gaurav Ghosh (USA)**
2. What are the equipment options and protocols used for esophageal manometry? – **Irene Sonu (USA)**
3. What are the indications for ambulatory reflux monitoring? – **Benjamin Rogers (USA)**
4. What are the equipment options and protocols used for objective reflux testing? – **Sravanya Gavini (USA)**
5. What are the indications for FLIP? – **Marc Wong (Hong Kong, China)**
6. What are the equipment options and protocols used for FLIP? – **Priya Kathpalia (USA)**

Panel Chat/Q&A

II. Metrics and Interpretation of Motility and Reflux Testing

Chairs: **C. Prakash Gyawali (USA)** – **Roger Tatum (USA)**

1. High-resolution manometry (HRM) metrics for esophageal motility interpretation – **Paul Menard-Katcher (USA)**
2. Interpretation of HRM – Chicago classification and special considerations. – **Diana Snyder (USA)**
3. What are the metrics used for ambulatory reflux monitoring interpretation? – **Yan Jiang (USA)**
4. Interpretation of ambulatory reflux testing – Lyon consensus and special considerations – **Marco Sozzi (Italy)**
5. What are the protocols and metrics used for FLIP interpretation? – **Allyson Richardson (USA)**
6. Interpretation of FLIP – Dallas consensus and special considerations. – **Anh Nguyen (USA)**

Panel Chat/Q&A

III. Esophageal Function Testing Interpretation Workshop

Chairs: **Anh Nguyen (USA)**

1. Achalasia spectrum disorder.
Presenters: **Marc Wong (Hong Kong)** – **Allyson Richardson (USA)** Discussant: **John O. Clarke (USA)**
2. Disorder of peristalsis: hypermotility disorder.
Presenters: **Diana Snyder (USA)** – **Paul Menard-Katcher (USA)** Discussant: **Ellen Stein (USA)**
3. Disorder of peristalsis: hypomotility disorder.
Presenters: **Irene Sonu (USA)** – **Priya Kathpalia (USA)**
Discussant: **José María Remes Troche (Mexico)**
4. Gastroesophageal reflux disease: unproven GERD: focusing on wireless pH monitoring.
Presenters: **Yan Jiang (USA)** – **Gaurav Ghosh (USA)** Discussant: **Roger Tatum (USA)**
5. Gastroesophageal reflux disease: proven GERD: focusing on pH-impedance monitoring.
Presenters: **Sravanya Gavini (USA)** – **Marco Sozzi (USA)** Discussant: **Walter W. Chan (USA)**
6. Behavioral syndrome (SGB plus rumination) focusing on pH impedance off therapy.
Presenters: **Akinari Sawada (Japan)** – **Benjamin Rogers (USA)** Discussant: **C. Prakash Gyawali (USA)**

Welcome to Versailles and to the *Opening Ceremony*

*You have come from Versailles, Paris, or even much farther away
to attend the 17th Congress of OESO.*

*We hope you'll take home fond memories of this event,
given everything we have prepared for you,
and not just for your scientific enrichment!*

Starting with this first day:

The actual start of the Opening Session is scheduled for **5:30 pm**
in the **Auditorium Richelieu of the Palais des Congrès**,

*You may have had the chance to visit the Carriage Gallery,
You may have experienced the Grandes Eaux Musicales with
our guide waiting for you at 2:00 pm*

The Opening Ceremony Program

Sunday, June 14 - 5:30 pm

■ Auditorium Richelieu

Master of Ceremony
Roger P. Tatum

Président du Domaine de Versailles
Mr Pierre-Emmanuel Lecerf

Founder of OESO – Deputy Executive Director
Robert Giuli

OESO President
John O. Clarke

Congress Presidents
Walter W. Chan – Arnulf Hölscher – Markus Moehler

Governor of the OESO-SEMPIRE Platform
Nikki Johnston

OESO Scientific Directors
C. Prakash Gyawali – Russell E. White

OESO Executive Director
Stefan P. Mönig

Following the introductory speeches, Professor Walter Chan, Harvard Medical School, Director of the Center for Gastrointestinal Motility, will welcome the participants in the
First OESO Esophageal Motility and Reflux Trainee Forum

Guest Lecturers:

Jean-Pierre Luminet *"La création du monde"*
Alexandre Maral *"Versailles, lieu de perfection de l'art français"*

The participants then head to the "Salle du Jeu de Paume" place of birth of French democracy, an historical site, accompanied by Mr Maral

before returning to the congress Center for a welcome reception.





DAY 2

Monday, June 15

Program

DAY 2 Monday, June 15

Session 1

Oncology: Multimodal therapy

Monday, June 15, 9:00 – 10:30 am

■ Auditorium Lulli

Chairs: **Markus Moehler (Germany)** – **Christelle De la Fouchardiere (France)** – **Manfred Lutz (Germany)**

1. Early-onset gastroesophageal cancer – a distinct entity? – **Irit Ben-Aharon (Israel)**
2. Pro: First choice Chemo (instead of CROSS) in adenocarcinoma of esophagus. – **Eduardo Terán (Spain)**
3. Contra: First choice CROSS (instead Chemo) in adenocarcinoma of esophagus. – **Mike Gibson (USA)**
4. Recurrences after neoadj therapy: local endoscopic resections or irradiation? – **Manfred Lutz (Germany)**
5. Management of Metastatic Disease. – **Aziz Zaanani (France)**
6. De-escalation strategies in oesogastric adenocarcinomas: is the time right? – **Christelle De la Fouchardiere (France)**
7. MSI: how do we treat, w+w or operate? – **Thierry André (France)**
8. ASCO 2026: New important SOC-changing phase III trials? – **Lucjan Wyrwicz (Poland)**
9. Multidisciplinary Tumor Board-Harmonizing other Local and Systemic Control in Gastric or Gastroesophageal Cancer. – **Hanoch Kashtan (Israel)**
10. Sport program and Resilience: what helps in perioperative setting? – **Katja Petrowski (Germany)**

Session 2

Functional Disorders – From Brain to Diaphragm and Back

Monday, June 15, 9:00 – 10:30 am

■ Auditorium Richelieu

Chairs: **Walter W. Chan (USA)** – **C. Prakash Gyawali (USA)**

1. Belch or no belch: what is the approach to belching disorders? – **Santosh Sanagapalli (Australia)**
2. When to suspect and confirm the diagnosis of rumination? – **Akinari Sawada (Japan)**
3. How do symptom-specific anxiety and hypervigilance intersect with esophageal conditions? – **Livia Guadagnoli (USA)**
4. What is the role of brain-gut behavioral therapy in treating esophageal symptoms? – **Megan Riehl (USA)**
5. How to leverage pharmacologic neuromodulation for esophageal symptoms. – **José María Remes Troche (Mexico)**
6. Are there roles for complementary therapies for treating esophageal symptoms? – **Chien-Lin (Harry) Chen (Taiwan)**

Panel Chat/Q&A

Day 2 Monday, June 15

Session 3

Distinguished Abstracts Plenary – Basic and Translational Science

Monday June 15, 09:00 – 10:30 am

■ Auditorium Condé

Chairs: **Mayssan Muftah (USA)** – **Nikki Johnston (USA)**

1. Prostaglandin E₂ Reverses Myofibroblast Differentiation in Eosinophilic Esophagitis. – **Amanda Muir (USA)**
2. VDTR-Net: An Integrated Dose-Toxicity Deep Learning Framework for Pre-Radiotherapy Planning Risk Assessment of Severe Radiation Pneumonitis in Esophageal Cancer. – **Yanhua Duan (China)**
3. Spatial analysis of CD8+ T cell neighbors using multiplexed immunofluorescence (MxIF) in esophageal squamous cell carcinoma (ESCC). – **Michael Gibson (USA)**
4. Amprenavir Protects Human Airway Cells from Pepsin-Induced Inflammation and Early Epithelial-Mesenchymal Transition. – **Karolina Lungova (USA)**
5. IL-13 induced β -catenin drives esophageal epithelial disruption. – **Amanda Muir (USA)**
6. Machine Learning to Predict Distant Metastasis Risk and Prognostic Analysis in T1 2 Esophageal Cancer: A Study Based on the SEER Database. – **Benben Zhu (China)**
7. Manometry-Only Distensibility Assessment: Inverted-Impedance 4D Manometry for Detecting Distension-Mediated Obstruction When the Functional Lumen Imaging Probe (FLIP) Is Unavailable. – **So Young Byun (Korea)**

Day 2 Monday, June 15

Session 4

Distinguished Abstracts Plenary – Clinical Research

Monday, June 15, 11:00 am – 12:30 pm

■ Auditorium Lulli

Chairs: **Ealaf Shemmeri (USA)** – **Pierfrancesco Visaggi (Italy)**

1. Prolonged One-Lung Ventilation Increases the Risk of Postoperative Pneumonia in Minimally Invasive and Robotic Esophagectomy. – **Vladimir Lozanovski (Germany)**
2. Higher Rates Of PPI Nonresponse With Proximal Stricture Compared To Distal Or No Stricture In Adults With Eosinophilic Esophagitis. – **David Hartnett (USA)**
3. Proposal of a Novel Endoscopic Classification to Assess Laparoscopic Fundoplication Validated with Clinical and Functional Outcomes. – **Stefano Siboni (Italy)**
4. Inverted Impedance-Based 4D Manometry Improves Achalasia Diagnosis by Assessing Esophagogastric Junction Distensibility When the Functional Lumen Imaging Probe (FLIP) Is Unavailable. – **So Young Byun (Korea)**
5. Clinical Outcomes After Curative and Noncurative Endoscopic Submucosal Dissection for Superficial Esophageal Cancer. – **Po-Kuei Hsu (Taiwan)**
6. A Retrospective Cohort Study Evaluating Textbook Outcomes and Long-Term Prognosis Following Esophagectomy. – **Benjamin Tordjman (Canada)**
7. High Dimensional Clustering Identifies Distinct Clinical Physiologic Phenotypes of Eosinophilic Esophagitis. – **Mayssan Muftah (USA)**
8. Efficacy of anti-reflux surgery on Laryngo-Pharyngeal Symptoms of Gastro-Esophageal Reflux Disease. – **Marco Sozzi (Italy)**
9. Diagnostic Performance of a Tegoprazan Based Therapeutic Trial in Patients with Suspected GERD: Interim Analysis of the Prospective Multicenter Phase IV TEGO-TEST study. – **Luis Raúl Valdovinos-Garcia (Mexico)**



Cinclus Pharma



Linaprazan glurate

- Investigational novel PCAB from Europe.
- Currently in clinical development for acid related diseases.
- HEEALING 1 – Phase 3 study for erosive GERD currently ongoing in Europe.

Learn more about our ongoing study program for the novel PCAB linaprazan glurate.



Day 2 Monday, June 15

Session 5

Functional Disorders – Talking Rome in Versailles

Monday, June 15, 11:00 am – 12:30 pm

■ Auditorium Richelieu

Chairs: **Daniel Sifrim (UK)** – **C. Prakash Gyawali (USA)**

1. How should non-cardiac chest pain be diagnosed? – **Ronnie Fass (USA)**
 2. How is functional heartburn different from reflux-induced heartburn? – **Ellen M. Stein (USA)**
 3. Should reflux hypersensitivity be managed as a DGBI, GERD, or both? – **Edoardo Savarino (Italy)**
 4. Is globus a LPRD symptom or a primary DGBI? – **José María Remes Troche (Mexico)**
 5. What test(s) should be performed to diagnose functional dysphagia? – **Sabine Roman (France)**
 6. How does functional dyspepsia overlap with esophageal symptoms or disorders? – **Braden Kuo (USA)**
- Panel Chat/Q&A

Session 6

Therapeutic Endoscopy: New Frontiers

Monday June 15, 11:00 am – 12:30 pm

■ Auditorium Condé

Chairs: **Mouen Khashab (USA)** – **Philip Chiu (Hong Kong)** – **Joo Ha Hwang (USA)** – **Byung-Wook Kim (Korea)**
Discussants: **Helmut Messmann (Germany)** – **Sung Kwan Shin (Korea)**

I. POEM and Third-Space Procedures

1. Does the side of mucosal entry affect POEM procedure outcomes? – **Toshitaka Hoppo (USA)**
2. What is the true incidence of reflux after POEM & how can that be reduced? – **Mouen Khashab (USA)**
3. Does it matter whether full-thickness or circular muscle-only myotomy is performed for POEM? – **Philip Chiu (Hong Kong)**
4. Do we know the long-term durability of POEM? – **Tomoaki Matsumura (Japan)**
5. Can we predict which patients will fail POEM? – **Ahmad Najdat Bazarbashi (Saudi Arabia)**
6. Should we aim for same day discharge after POEM? – **Silvana Perretta (France)**

II. Endoscopic Submucosal Dissection & Tumor Resection

7. How large is too large for ESD in 2026? – **Cheol Woong Choi (Korea)**
8. How deep is too deep for ESD in 2026? – **Ahmad Najdat Bazarbashi (Saudi Arabia)**
9. Is endoscopic ultrasound helpful or required for optimal ESD? – **Helmut Messmann (Germany)**
10. Will artificial intelligence change the way we perform ESD? – **Moon Kyung Joo (Korea)**
11. What technological advances are needed for ESD to make the next leap forward? – **Shai Friedland (USA)**
12. What are the next steps for 3rd space endoscopy in the esophagus? – **Anthony Kalloo (USA)**

Day 2 Monday, June 15



Lunch Symposium A

sponsored by AstraZeneca

Navigating Gastroesophageal Cancer Care: a Case-based Discussion.

Monday, June 15, 12:45 – 1:45 pm

■ Auditorium Lulli



Lunch Forum

(by invitation only)

OESO Esophageal Motility and Reflux Trainee Forum

Monday, June 15, 12:45 – 1:45 pm

■ Room Boileau



Lunch Symposium D

sponsored by MIMEDX

Human Placental Allografts as a Protective Barrier After Complex Esophageal Anastomoses in High-Comorbidity Patients.

Monday, June 15, 12:45 – 1:45 pm

■ Room Montesquieu

Day 2 Monday, June 15



Session 7

Laryngopharyngeal Reflux Disease (LPRD): Cutting Through the Noise

Monday, June 15, 2:00 – 3:30 pm

■ Auditorium Lulli

Chairs: **Frank Zerbib (France)** – **Nikki Johnston (USA)**

1. What does the San Diego Consensus change in clinic? – **Thomas L. Carroll (USA)**
2. What is the value in establishing a new ICD-10 CM code for LPRD? – **Alexandra Vandenberg (USA)**
3. Is GMA biomarker subtyping the key to understanding and treating GERD/LPR? – **Mark Noar (USA)**
4. Alginate, H2RA, PPI, neuromodulation, or lifestyle first – what's your first script? –
Jacqui Allen (New Zealand)
5. What is the role of sedated POEM procedures for UES issues? – **Pavan Mallur (USA)**
6. What is your oropharyngeal dysphagia management protocol for LPR? – **Derrick Randall (Canada)**
7. What are the pathogenic elements of refluxate in LPRD: acid, pepsin, bile, and beyond? –
Tina Samuels (USA)
8. What is the status of pepsin inhibitors for LPR? – **Nikki Johnston (USA)**
9. What is the current understanding of the role of reflux in promoting laryngopharyngeal cancer? –
Jérôme R. Lechien (Belgium)
10. Which surgical or endoscopic options work for extra-esophageal disease? – **Stefano Siboni (Italy)**

Structured Debate:

Motion: “This house supports the San Diego Consensus Statement as the governing guideline for LPRD.”

FOR: **Walter W. Chan (USA)** – (defending the Consensus statements & pathways).

AGAINST: **Mark Noar (USA)** – (challenging external validity, symptom-first pathways, and laryngology-specific nuances).

Case-Based Panel + Audience Interaction:

All panelists on stage for questions and discussion: **Jonathan Bock (USA)** – **Jacqui Allen (New Zealand)** – **Mark Noar (USA)** – **Edoardo Savarino (Italy)** – **Serhat Bor (Turkey)** – **Stefano Siboni (Italy)** – **Jérôme R. Lechien (Belgium)** – **Thomas L. Carroll (USA)**

1. Chronic cough with normal acid exposure but high non-acid events: “Does therapy change?”
Panel lead: **Jonathan Bock (USA)**
2. Mucosal protection: formulations and their place in the management of GERD and LPR.
Panel lead: **Serhat Bor (Turkey)**
3. Refractory LPS after maximal PPI & alginate: “Is it time for surgery or is it not reflux?”
Panel lead: **Stefano Siboni (Italy)**

Navigating gastroesophageal cancer care: a case-based discussion

Monday, 15 June 2026 | 12:45–13:45 CEST

Lulli Room – Versailles Palais des Congrès, Versailles, France



Christelle de la Fouchardière, MD

Institut Paoli-Calmettes,
Marseille, France



Lucjan Wyrwicz, MD, PhD

Maria Skłodowska-Curie National Cancer
Research Institute, Warsaw, Poland



Guillaume Piessen, MD

Centre Hospitalier Régional
Universitaire de Lille, Lille, France



Mar Iglesias Coma, MD

Hospital del Mar, Pompeu Fabra
University, Barcelona, Spain

Time (CEST) PROGRAMME

12:45–12:50 Welcome and introductions
Christelle de la Fouchardière

12:50–13:00 Plenary: Optimising the patient journey in resectable gastroesophageal cancer
Lucjan Wyrwicz

13:00–13:15 Panel discussion: Case-based discussion for resectable gastroesophageal cancer
Audience Q&A
Moderator: Lucjan Wyrwicz
All faculty

13:15–13:25 Plenary: Considerations for biomarker-targeted treatment of advanced gastroesophageal cancer
Christelle de la Fouchardière

13:25–13:40 Panel discussion: Case-based discussion for advanced gastroesophageal cancer
Audience Q&A
Moderator: Christelle de la Fouchardière
All faculty

13:40–13:45 Close
Christelle de la Fouchardière

All sessions include audience participation through voting / polling.

This non-promotional scientific exchange symposium is organised and funded by AstraZeneca for healthcare professionals only.

During this symposium, data may refer to medicines or indications under investigation or that may not be approved in your country. The information should under no circumstances be regarded as a recommendation for use of the medicine or indication. Please consult your local prescribing information.

Day 2 Monday, June 15

Session 8

Robotic Surgery

Monday, June 15, 2:00 – 03:30 pm

■ Auditorium Richelieu

Chairs: **Inderpal (Netu) Singh Sarkaria (USA)** – **Matthew Read (Australia)**
– **Andrés Francisco Navarrete Molina (Chile)**

1. Why and when to resect thoracic duct during RAMIE and in which anatomical plane? – **Hiroyuki Daiko (Japan)**
2. da Vinci Single Port subcostal Esophagectomy – How to and first results? – **Jasmina Kuvendjiska (Germany)**
3. Cardia Cancer – how to treat different compared to esophageal AC? – **Andrés Francisco Navarrete Molina (Chile)**
4. Vision of Robot Assisted Cervical Esophagectomy (RACE). – **Peter Grimminger (Germany)**
5. Results of the randomized prospective multi-center ROBOT-2 Trial of MIE vs RAMIE. – **Felix Berlth (Germany)**
6. Different robotic systems (also for esophageal surgery) what does make sense? – **Simone Giacomuzzi (Italy)**

Panel Chat/Q&A

Session 9

LKCHUGR-OESO Joint Session on Global Perspectives in Advanced Endoscopic Techniques

Monday June 15, 2:00 – 3:30 pm

■ Auditorium Condé

Chairs: **Byung-Wook Kim (Korea)** – **Hwoon-Yong Jung (Korea)** – **Stefan Mönig (Switzerland)**
Discussants: **Sung Kwan Shin (Korea)** – **Eun Ji Shin (USA)** – **Helmut Messmann (Germany)**

1. ESD in superficial esophageal cancer – reflecting Korea's high volume and advanced endoscopic techniques. – **Da Hyun Jung (Korea)**
2. EMR vs ESD for superficial esophageal cancer in the West. – **Seung-Hun Chon (Germany)**
3. Real-world evidence of POEM for achalasia. – **Hyo-Joon Yang (Korea)**
4. Endoscopic management of Zenker's Diverticula. – **Mouen Khashab (USA)**
5. AI-assisted endoscopic diagnosis of esophageal dysplasia or cancer. – **Chang Seok Bang (Korea)**
6. Evaluation and management of esophageal subepithelial masses. – **Walter Park (USA)**

Keynote Lecture: Evaluation and management of recurrent dysphagia in patients with achalasia previously treated with POEM. – **Joo Ha Hwang (USA)**

The OESO-SEMPIRE



Stanford
MEDICINE

SEMPIRE

Stanford Esophageal Multidisciplinary
Program in Innovative Research Excellence

The result of more than 3 decades of cooperative work by OESO

An Organization that brings together in a single scientific perspective specialists from all clinical and fundamental disciplines, illustrated by

- 17 World congresses, whose original Question & Answer format has become an institutional format,
- An evolving Encyclopedia of Esophagology, which today includes 12 volumes,
- Collaboration with UNESCO (2 Chairs in Telemedicine) and with the New York Academy of Sciences,
- A Foundation, whose purpose is to support the fulfillment of the goals of OESO.

... and, since 2018, an active association with Stanford University for the creation and launching of a major joint training and education project:

**The OESO-SEMPIRE Educational Platform
35 Pilot Centers**

are brought together in this poly-disciplinary platform.

Day 2 Monday, June 15

Session 10

Pilot centers

Monday, June 15, 4:00 – 05:30 pm

■ Auditorium Lulli

- Introduction and new perspectives.
Nikki Johnston (USA) – Robert Giuli (France) – Dhanpat Jain (USA)
- Technological updating of the OESO-SEMPIRE Platform.
Rahul Bharadwaj (Malaysia)
- Proposals from Pilot Centers.
Jérôme R. Lechien (Belgium) – Frank G. Ondrey (USA) – Peter Pokieser (Austria)
- Chat discussion.
Philip Chiu (Hong Kong) – Suzanne Gisbertz (the Netherlands) – Ines Gockel (Switzerland) – Matthew Read (Australia) – Russell E. White (Kenya) – Frank Zerbib (France) – Bruno Zilberstein (Brazil)

Session 11

Robotic Surgery

Monday, June 15, 4:00 – 05:30 pm

■ Auditorium Richelieu

Chairs: **Flavio Takeda (Brasil) – Yusef Kudsi (USA) – Peter Grimmering (Germany)**

1. ICG during RAMIE. – **Jennifer Klasen (Switzerland)**
 2. RAMIE in South America vs. North America.
– **Rubens Sallum (Brazil) – Inderpal (Netu) Singh Sarkaria (USA)**
 3. RAMIE in difficult Cases – Proximal esophagus. – **Felipe Victor (Brazil)**
 4. New Techniques treating early cancer with robotic surgery vs. endoscopy. – **Silvana Peretta (France)**
 5. Benign Foregut – Robotic Update. – **Tanuja Damani (USA)**
 6. Implementation of AI / Digital Assist in robotic surgery / Innovation. – **Tilman Schlick (Germany)**
- Panel Chat/Q&A

Human Placental Allografts as a Protective Barrier After Complex Esophageal Anastomoses in High-Comorbidity Patients

YOU ARE INVITED TO:

A presentation by Dr. med. Yves Borbély discussing published clinical studies^{1,2} and real-world experience on the use of AMNIOFIX® placental allografts as a protective barrier on exposed tissues after esophageal anastomosis surgery.

Drawing from clinical experience, he will discuss observed patient benefits with AMNIOFIX and highlight case examples.



AMNIOFIX®



- Dehydrated Human Amnion/Chorion Membrane
- Provides a protective barrier and thereby supports the healing process

FEATURED SPEAKER



Dr. med. Yves Borbély
General and Visceral Surgery
Bern, Switzerland



SAVE THE DATE

Monday, 15.06.2026 | 12:45 – 13:45
OSEO World Conference
Room: Montesquieu

FIND OUT MORE

Scan the code to contact
Chris Latford or email
clatford@mimedx.com



1. Carrtion K, et al. Plast Reconstr Surg Glob Open. 2025 May 16;13(Suppl 2):137-138. 2. Miller DL, et al. Ann Thorac Surg. 2022;114(2):e137-e139.

Day 2 Monday, June 15

Session 12

Eosinophilic Esophagitis: State of the Art

Monday June 15, 4:00 – 5:30 pm

■ Auditorium Condé

Chairs: **Nirmala Gonsalves (USA)** – **Pierfrancesco Visaggi (Italy)**

Discussants: **Jennifer Horsley-Silva (USA)** – **Emily McGowan (USA)**

I. Diagnosis, Clinical Presentation & Pathophysiology

1. What is the true prevalence of EoE and is it increasing? – **Mayssan Muftah (USA)**
2. What do we know about the microbiome in EoE or assessing endoscopic severity? – **Alex Strauss (USA)**
3. Is an allergist required for care of the EoE patient in 2026? – **Emily McGowan (USA)**
4. What are the advantages of “EoE Diagnostic Panel (EDP)” over peak eosinophil count for EOE diagnosis? – **Kevin Waters (USA)**
5. What is the role for non-endoscopic techniques for diagnosis & surveillance? – **John O. Clarke (USA)**
6. Challenges in evaluating biopsies in suspected EOE cases? – **Kevin Waters (USA)**

Panel Chat/Q&A

II. Management

7. Is there still a role for proton pump inhibitors in the management of EoE? – **Ellen Stein (USA)**
8. Topical steroids: who, what & how long? – **Jennifer Horsley-Silva (USA)**
9. How to approach biologic therapies for EoE in 2026? – **Joshua Sloan (USA)**
10. How I approach endoscopic dilation for EoE – **William Ravich (USA)**
11. What to do with the EoE patient who becomes pregnant? – **Claire Beveridge (USA)**
12. Is EoE therapy forever? – **Calies Menard-Katcher (USA)**

Panel Chat/Q&A

Day 2 Monday, June 15

Poster Session

Poster Exhibition

Monday June 15, 05:30 – 06:30 pm

■ Mazarin Hall

Chair: **Walter W. Chan (USA)**

Gastroenterology

G01 – Ninety-Six-Hour, Ambulatory pH Monitoring Is Superior to Forty-Eight-Hour pH Monitoring in Establishing Pathologic Esophageal Acid Exposure in Patients With GERD Symptoms. **Shafi Mehnaez**

G02 – Acid Exposure Profiles in Patients with Potassium-competitive Acid Blockers Refractory Heartburn: A Multi-center Retrospective Study Using 24-Hour Ambulatory pH Monitoring. **Kim Sujin**

G23 – Distinct Phenotype of Eosinophilic Esophagitis in Korea: A Nationwide Population-Based Retrospective Cohort Study. **Lee Sang Pyo**

G31 – Prophylactic fluticasone inhalation for post-endoscopic submucosal dissection esophageal stricture: a single-arm pilot study. **Kim Yuri**

G03 – Effectiveness and Patient Satisfaction with Zastaprazan in Real-World Practice: A Large-Scale Prospective Observational Study. **Seo Seung In**

G39 – Esophageal Ulceration in Suspected Gastrointestinal Behçet Disease: A Diagnostic Challenge. **Le Thuy**

G04 – Proton pump inhibitors and gastric cancer: A large-scale propensity score-matched analysis. **Jung Da Hyun**

G18 – Normative Values for Esophagogastric Junction and Pyloric Distensibility Using EndoFLIP in Healthy Korean Adults. **Noh Jin Hee**

G05 – Reflux esophagitis is an independent predictor for co-morbid insomnia and sleep apnea (COMISA): a prospective study with home sleep testing in a general population. **Hu Kai-Yu**

G24 – Efficacy and Compliance of Food Elimination Diet in Adult Eosinophilic Esophagitis. **Kotryna Truskaite**

G06 – Predictive factors of the Stretta procedure for treating GERD. **Cho Yu Kyung**

G19 – Striated Esophageal Contractility: A Novel Biomarker in Parkinson's Disease Patients Without Dysphagia. **Joo Moon Kyung**

G07 – Low Acid Exposure May Not Exclude GERD: Adjunctive Criteria Identify GERD-Like Physiology in Asian Patients. **Le Thuy**

G08 – Optimising Fexuprazan Treatment Duration for Endoscopic Submucosal Dissection-Induced Artificial Gastric Ulcers: A Multicentre, Randomised, Active-Controlled Trial. **Jung Da Hyun**

G25 – Dupixent Dosage Decisions: Exploring the Histologic Trend for a Change From Weekly to Every Other Week in EoE. **Kristle Lynch**

G26 – EoE Response Rates in Real Life. **Kristle Lynch**

G27 – Hard to Swallow: Treatment Adherence Challenges in Eosinophilic Esophagitis. **Kristle Lynch**

G35 – Risk Factors for Esophageal Stricture Following Definitive Chemoradiotherapy for Esophageal Squamous Cell Cancer. **Jeon Seong Woo**

G36 – Efficacy and Safety of Peroral Endoscopic Myotomy: A Single Center Retrospective Study. **Kim Sung Eun**

G21 – Clinical outcomes and safety of per-oral endoscopic myotomy and the diagnostic value of Endo-luminal Functional Lumen Imaging Probe: A single-center retrospective study. **Kim Sung Eun**

G28 – Prevalence of GERD in Patients with Eosinophilic Esophagitis and Its Impact on Treatment Outcomes: Insights from a Swedish Tertiary Centre Cohort. **Kotryna Truskaite**

G09 – Efficacy and Safety of Tegoprazan in Patients with Globus Sensation: A Randomized, Double-blind, Placebo-controlled Pilot Trial. **Lim Chul-Hyun**

Poster Session cont.

G10 – Addressing the Coding Gap: Justification for Novel ICD-10-CM Codes for Laryngopharyngeal Reflux Disease (LPRD). **Ally Vandenberg**

G37 – EMR and Endoscopic mucosal dissection (ESD) for early esophageal neoplasia : A single center experience in South Korea. **Jee Samryong**

G11 – Refining Mean Nocturnal Baseline Impedance Thresholds for Gastroesophageal Reflux Disease in an Asian Population Across Different Diagnostic Frameworks. **Lei Wei-Yi (Ray)**

G13 – COUGH RefluX Score Stratifies Reflux Burden in Patients with Laryngopharyngeal Symptoms but Is Not Associated with Symptom Severity or Psychological Distress. **Wong Ming-Wun**

G29 – Index of Severity for Eosinophilic Esophagitis (I-SEE) Score at Initial Presentation of Newly Diagnosed EoE Predicts Proton Pump Inhibitor Response. **Muftah Mayssan**

G30 – Increased Disease Severity as Measured by I-SEE in Patients with Newly Diagnosed Eosinophilic Esophagitis Predicts Subsequent Esophageal Dilation and Food Impaction. **Muftah Mayssan**

G14 – Prevalence of Pathological GERD and the Role of Esophageal Hypervigilance and Anxiety in PPI-Dependent Patients Seeking Anti-Reflux Mucosal Ablation. **Chen Chien-Lin**

G16 – Evaluation of supragastric belching using upright time adjusted frequency. **Satsuki Takahashi**

G38 – Endoscopic Incisional Therapy versus Balloon Dilatation as Primary Treatment for Benign Esophageal Strictures: Efficacy and Safety Outcomes. **Kim Dong Woo**

Oncology

O62 – Prognostic Impact of Prior Malignancy in Esophageal Squamous Cell Carcinoma. **Yu Suna**

O63 – Primary esophageal MALT lymphoma mimicking a subepithelial tumor and successfully controlled with radiotherapy after recurrence: a case report. **Choe Younghee**

O66 – Effectiveness of long-term esophageal cancer screening program in China: a comparative analysis of incidence, mortality and survival between screened and non-screened regions. **Sun Kexin**

O – Cancerous diseases of the oral cavity larynx and esophagus. **Frank Ondrey**

Surgery

S45 – Non-malignant Esophageal Perforations: Survival vs Non-Survival and Predictors of Outcome in a Quarter-Century Single-Center Cohort. **Philipp Gehwolf**

S48 – Da Vinci Single-Port Subcostal Ivor-Lewis Esophagectomy (SP SC RAMIE) – Unlocking the Potential of a Single-Port Approach. **Vladimir J. Lozanovski**

S56 – Thoracic duct preservation in esophageal cancer surgery - Is there a potential? **Christoph Wandhöfer**

S54 – Right-First Bilateral Transcervical Single-Port Robotic Esophagectomy: A Cadaveric Feasibility Study Toward a Safer Extrapleural Strategy. **Olga Meier**

S55 – Transitioning from Thoracoscopic to Robotic McKeown Esophagectomy: Early Perioperative Outcomes from a Single-Surgeon Experience. **Hsu Po-Kuei**

S42 – Toupet Fundoplication Is An Adequate Procedure For Patients With Severe Gastro-Esophageal Reflux Disease. **Stefano Siboni**

S57 – Perioperative FLOT plus Durvalumab in gastric and gastroesophageal junction adenocarcinoma: early real-world evidence on surgical safety and feasibility. **Alba Martín del Rey**

S43 – Dysphagia after surgical treatment of GERD. **Felix Valter Nilton**

S47 – Aorto-esophageal fistula after surgical repair of an aortic dissection associated to Kommerell aneurysm: A case report. **Ivet Goujon**



DAY 3

Tuesday, June 16

Program

Session 13

GI Clinical Pharmacology & Therapeutics

Tuesday June 16, 9:00 – 10:30 am

■ Auditorium Lulli

Chairs: **Carmelo Scarpignato (Malta)** – **C. Prakash Gyawali (USA)**

I – Acid Suppression: Present and Future

1. Acid Suppression: Limitations of the Current Antisecretory Drugs. Why do PPIs fail in some patients, and what are the true boundaries of acid suppression? – **Justin Wu (Hong Kong)**
2. Potassium-competitive Acid Blockers (P-CABs): A Step Forward in Acid Suppression. Do they really represent a paradigm shift or just an incremental advance? – **Carmelo Scarpignato (Malta)**
3. P-CABs for GERD: When and How. Patient profiles, timing, and switching strategies. – **Ronnie Fass (USA)**
4. Alginate-containing Formulations: Before, With, or After PPIs? Optimizing the synergy between mechanical and pharmacologic acid control. – **Serhat Bor (Turkey)**

II – Mucosal Protection and Beyond

5. Mucosal Protective Compounds for GERD: How Much Are They Effective? Evidence and clinical relevance of sucralfate, hyaluronic acid–chondroitin sulfate, and similar agents. – **Daniel Sifrim (UK)**
6. The Status of Pepsin Inhibitors for PPI-Refractory GERD and LPR. A promising approach or another dead end? – **Nikki Johnston (USA)**

III – Motility & Neuromodulation

7. GI Prokinetics: Which Role in GERD? From metoclopramide to acotiamide—any real progress? – **José María Remes Troche (Mexico)**
8. When Are Neuromodulators Indicated in GERD? Functional heartburn, reflux hypersensitivity, and esophageal perception. – **C. Prakash Gyawali (USA)**

IV – Eosinophilic Esophagitis (EoE)

9. PPIs or Steroids for EoE: Alone or in Combination? Balancing efficacy, safety, and long-term management. – **Nirmala Gonsalves (USA)**
10. EoE: When to Start Biologic Therapy and How? Current position of anti-IL-13/IL-4 agents and future perspectives. – **Nicola De Bortoli (Italy)**

V – Motor Disorders & New Frontiers

11. Smooth Muscle Relaxants for Achalasia: Still a Bridge Treatment? Are pharmacologic options still relevant in the POEM era? – **Mark Fox (Switzerland)**
12. Long-term Safety and Pharmacogenetics of Acid Suppression. Are we ready for tailored therapy and precision acid suppression? – **Walter W. Chan (USA)**
13. Reflux Inhibitors: A Promise Unfulfilled or a Niche Therapy? Targeting TLESRs: Translational Failures and Clinical Residues. – **Ellen Stein (USA)**

Day 3 Tuesday, June 16

Session 14

Esophageal Cancer – Best Surgical Treatment for Esophageal Adenocarcinoma

Tuesday June 16, 9:00 – 10:30 am

■ Auditorium Richelieu

Chairs: **Arnulf Hölscher (Germany)** – **Giovanni De Manzoni (Italy)** – **Stefan Mönig (Switzerland)**

1. Which classification system we need 2026? – **Giovanni De Manzoni (Italy)**
 2. Double Tract reconstruction after limited resection. – **Johannes Zacherl (Austria)**
 3. How long we can wait after neoadjuvant treatment for surgery and how long we should wait? – **Mickael Chevallay (Switzerland)**
 4. Which access is the best open, HYBRID or minimal invasive? – **Frank Benedix (Germany)**
 5. What is the safest anastomotic technique after esophagectomy? – **Paul Schneider (Switzerland)**
 6. How we can prevent and treat Enterothorax after Esophagectomy? – **Christian Gutschow (Switzerland)**
- Panel Chat/Q&A

Session 15

Techniques and Tips in Esophageal Practice: GERD, Antireflux Surgery, and Esophageal Cancer

Tuesday June 16, 9:00 – 10:30 am

■ Auditorium Condé

Chairs: **Roger Tatum (USA)** – **Benjamin Rogers (USA)**

1. How to approach Tissue Cypher in the low vs. high risk patients with Barrett's esophagus. – **Allon Kahn (USA)**
2. How to approach chronic belching, what's my personal approach. – **Johannes Lenglinger (Switzerland)**
3. How I work up and manage the manometric finding of absent peristalsis. – **Ping-Huei Tseng (Taiwan)**
4. How I approach refractory reflux, before pre-operative work up. – **Rishi Naik (USA)**
5. Patient selection for magnetic sphincter augmentation vs. fundoplication. – **Kourtney L. Kemp (USA)**
6. When and how to remove the magnetic sphincter augmentation device. – **Nainika Menon (UK)**
7. Workup and surgical procedure selection in GERD patients with morbid obesity. – **Judy Chen (USA)**
8. Patient selection for and technique of the reflux stop procedure. – **Yves Borbely (Switzerland)**
9. Management of patients with post-antireflux surgery gastroparesis. – **Jacob Moremen (USA)**

Day 3 Tuesday, June 16

Case training

Dynamic Imaging: Case training for multi-level dysphagia

Tuesday June 16, 9:00 – 10:30 am

■ Room Montesquieu



OESO offers tickets for three live sessions on "**Deglutology meets Esophagology**".

Videofluoroscopy can investigate the oropharyngeal and the esophageal phase with a single investigation.

Our aim is to present the recent capabilities of Videofluoroscopy of the entire upper GI tract by a multidisciplinary expert team to discuss the value of Videofluoroscopy to diagnose pathologic findings even on multiple sites along the swallowing pathway. Further the perspective of referring clinicians will be discussed for best use and therapeutic value of dynamic imaging.

[Registration Live Sessions – Deglutology meets Esophagology](#) >

We offer a complete overview of the current technique of Videofluoroscopy in three sessions live on **June 16, 2026 from 12:00 noon to 05:30 pm CEST**,

with international remote access for three months:

Session 12 noon – 1:30 pm

Case presentations on "Multilevel Dysphagia" – **Peter Pokieser (Austria)**

Session 02:00 – 03:30 pm

Dynamic Radiology I: Multidisciplinary expert panel – 6 statements on dynamic morphological findings of the upper GI tract: expert panel. – **Peter Pokieser (Austria)** – **Johannes Zacherl (Austria)** – **William Ravich (USA)** – **Ludwig Kramer (Austria)**

Session 04:00 – 05:30 pm

Dynamic Radiology II: Multidisciplinary expert panel - 6 statements on dynamic functional findings of the upper GI tract: expert panel. – **Nathalie Rommel (Belgium)** – **Peter Pokieser (Austria)** – **Ayodele Sasegbon (UK)** – **Johannes Zacherl (Austria)** – **Jaqueline Allen (New Zealand)**

Global reach

OESO is truly global in scope, with

10,000+ corresponding members

85+ countries represented

19 specialties collaborating under one umbrella

35 Pilot Centers

A worldwide network of Pilot Centers advancing clinical education

The OESO-SEMPIRE platform and Gatherings in Esophagology (GiE) enable virtual and physical exchanges that connect clinicians and researchers worldwide, ensuring OESO's reach extends to both developed and developing regions.

Day 3 Tuesday, June 16

Session 16

Artificial Intelligence and Digital Technology in Esophagology

Tuesday, June 16, 11:00 am – 12:30 pm

■ Auditorium Lulli

Chairs: **Lee L. Swanström (France)** – **Gretchen Purcell Jackson (USA)**

1. Current status of AI in Medicine/ barriers and opportunities. – **Filippo Filicori (USA)**
2. AI and Digestive radiology – better? Easier? – **Peter Pokieser (Austria)**
3. AI and Barretts – where are we? – **Jason Samarasena (USA)**
4. AI for esophageal function testing. – **Benjamin Rogers (USA)**
5. AI for reflux monitoring interpretation. – **Benjamin Rogers (USA)**
6. Can AI make me a better esophageal surgeon? – **Jonathan DeLong (USA)**
7. AI and the robot – synergy? – **Gretchen Purcell Jackson (USA)**
8. AI and coordinated care of the esophagus. – **Eric Shah (USA)**
9. Can AI improve the pathologic diagnosis of BE and how?" – **Maha M. Guindi (USA)**
10. Can a digital morphometry in AI improve the histological diagnosis of EoE? – **Rupert Langer (Austria)**
11. AI and EGD quality – **Lee L. Swanström (France)**

Panel discussion: Favorite AI tool for my practice.

Moderators: **Lee L. Swanström (France)** – **Gretchen Purcell Jackson (USA)**

Discussants: **Jonathan DeLong (USA)** – **Benjamin Rogers (USA)** – **Jason Samarasena (USA)** – **Eric Shah (USA)** – **Rupert Langer (Austria)** – **Anastasia Bartashova (Austria)** – **Filippo Filicori (USA)**

Session 17

Esophageal Cancer – Special Aspects for Treatment of Squamous Cell Esophageal Carcinoma

Tuesday, June 16, 11:00 am – 12:30 pm

■ Auditorium Richelieu

Chairs: **Vincent Wentao Fang (China)** – **Peter Grimminger (Germany)** – **Guido Schumacher (Italy)**

1. Is there a place for surgery in proximal cancer? – **Ian Wong (Hong Kong)**
2. When we need McKeown, when Ivor-Lewis approach is sufficient? – **Rubens Sallum (Brazil)**
3. What is necessary extent of lymphadenectomy in thoracic esophageal cancer? – **Ines Gockel (Switzerland)**
4. Technical aspects of cervical anastomosis after McKewon esophagectomy? – **Jari Räsänen (Finland)**
5. What are the arguments for surgery in squamous cell carcinoma? – **Guillaume Piessen (France)**
6. What are the pitfalls for salvage esophagectomy? – **Felix Berlth (Germany)**

Panel Chat/Q&A



**combattre
simultanément
plus de 30 cancers**

Parce que la santé a besoin d'audace.

Les chercheurs de MSD développent des traitements contre plus de 30 cancers. Leurs travaux, combinés à l'excellence de la recherche clinique française, ont permis à plus de 3000 patients en France de participer à nos essais cliniques et d'accéder ainsi plus rapidement aux innovations thérapeutiques telles que l'immunothérapie.



MSD
INVENTING FOR LIFE

Day 3 Tuesday, June 16

Session 18

KSNM-OESO Joint Session: Esophagology – East vs West

Tuesday June 16, 11:00 am – 12:30 pm

■ Auditorium Condé

Chairs: OESO representatives: **Kerry Dunbar (USA) – Amanda Muir (USA)**
KSNM representatives: **Moo In Park (Korea) – Sang Kil Lee (Korea)**
Discussants: OESO representative: **Albis Hani (Colombia)**
KSNM representative: **Jung-Hwan Oh (Korea)**

GERD

1. Approach to GERD in the Western population: what's beyond Lyon? – **C. Prakash Gyawali (USA)**
2. Clinical Limitations of the Lyon Consensus 2.0 in Asian Populations. – **Yu Kyung Cho (Korea)**

Motility

3. When testing modalities disagree: Rethinking diagnostic hierarchies in esophageal physiology. – **Walter W. Chan (USA)**
4. Esophageal motility diagnostics in Asia: Epidemiology, testing trends, and unmet needs. – **Ju Yup Lee (Korea)**

Eosinophilic Esophagitis

5. Phenotypes of eosinophilic esophagitis: Impact on presentation, diagnosis, and management. – **Amanda Muir (USA)**
6. Eosinophilic esophagitis in Asia: Distinct clinical and endoscopic profiles compared with the West. – **Kee Wook Jung (Korea)**

Keynote Lecture: (by KSNM speaker): **Do Hoon Kim (Korea)**

Comparative Effectiveness of P-CAB vs PPI: Real-World Evidence

Lunch Symposium B

sponsored by MSD

Redefining Care in Unresectable and Metastatic Esophageal Cancer.

Tuesday, June 16, 01:00 – 01:45 pm

■ Auditorium Lulli



Old Problem, New Answer Tegoprazan

Acid Suppression Redefined

Day 3 Tuesday, June 16

Lunch Symposium C *sponsored by inno.N*

Tegoprazan: New Clinical Evidence and Expanding Therapeutic Perspective.

Monday, June 15, 12:45 – 1:45 pm

■ Auditorium Lulli

Session 19

Surgical Endoscopy: Pushing the envelope of what can be done with the endoscope

Tuesday, June 16, 2:00 – 3:30 pm

■ Auditorium Lulli

Chairs: **Eun Ji Shin (USA)** – **Lee L. Swanstrom (France)** – **Toshitaka Hopppo (USA)**

Endoscopic Reflux Therapy

1. Is anti-reflux mucosectomy ready for prime-time? – **Ping-Huei Tseng (Taiwan)**
2. Who is the ideal patient for transoral incisionless fundoplication (TIF)? – **Medhat Fanous (USA)**
3. Why do c-TIF instead of a standard fundoplication? – **Reginald Bell (USA)**
4. What is the long-term success & durability of TIF? – **Kenneth Chang (USA)**
5. How large a hernia is too large to address with c-TIF? – **Marcia (Mimi) Canto (USA)**
6. Can AI help us better predict which endoscopic therapy is most likely to be successful?
– **Lee L. Swanström (France)**

Complications of Endoluminal Intervention

1. How to approach mucosal erosion from the magnetic device? – **Emanuele Asti (Italy)**
2. What are the key complications to be aware of from TIF or cTIF? – **Reginald Bell (USA)**
3. How to approach a blown-out myotomy? – **Daryl Ramai (USA)**
4. What is the optimal way to address significant reflux after POEM? – **Valter N. Felix (Brazil)**

Keynote Talk: What will the frontiers of surgical endoscopy be in the next 20 years?

– **Philip Chiu (Hong Kong)**

Day 3 Tuesday, June 16

Session 20

Eosinophilic Esophagitis – Hot Topics & Unanswered Questions

Tuesday June 16, 2:00 – 3:30 pm

■ Auditorium Richelieu

Chairs: **John O. Clarke (USA)** – **Walter W. Chan (USA)**

1. Do we really know what causes EoE? – **Amanda Muir (USA)**
2. What is the role for allergy testing for EoE patients? – **Emily McGowan (USA)**
3. How should one ideally pursue an EoE-elimination diet? – **Claire Beveridge (USA)**
4. How to approach medical therapy for EoE: my algorithm? – **Christoph Schlag (Switzerland)**
5. What is the role for artificial intelligence in EoE? – **Pierfrancesco Visaggi (Italy)**
6. How will we treat EoE in 10 years? – **Nirmala Gonsalves (USA)**

Panel Chat/Q&A

Session 21

Dynamic Imaging 1 – Dynamic Esophagology Morphology

Tuesday June 16, 2:00 – 3:30 pm

■ Auditorium Condé

Chairs: **Peter Pokieser (Austria)** – **Johannes Zacherl (Austria)**

1. What is the additional value of dynamic radiology for the esophagus with 25 or 30 frames per second? – **William Ravich (USA)**
2. Why dynamic radiology is the best test to measure single and multiple stenoses of the esophagus? – **Peter Pokieser (Austria)**
3. Is there any use of dynamic fluoroscopy in patients with esophageal carcinoma? – **Inderpal (Netu) Singh Sarkaria (USA)**
4. Surgery of benign diseases of the PE-segment: what are the demands for dynamic radiology? – **Johannes Zacherl (Austria)**
5. Bariatric surgery: is there a role for dynamic radiology for late postoperative complications? – **Peter Pokieser (Austria)**
6. Esophagology and Gastroenterology: are there indications for dynamic radiology? – **Ludwig Kramer (Austria)**

Panel Chat/Q&A

Day 3 Tuesday, June 16

Session 22

Oncology: Palliative treatment and more

Tuesday, June 16, 4:00 – 5:30 pm

■ Auditorium Lulli

Chairs: **Manfred Lutz (German)** – **Anneli Elme (Estonia)** – **Mike Gibson (USA)**

1. ESMO standards of care: equal to other countries in the world? – **Jonas Feilchenfeldt** (Switzerland)
2. Eastern Perspectives on Esophageal Cancer – Exploring Regional Differences in Clinical Characteristics and Treatment Strategies, with a Focus on ESD. – **Hwoon-Yong Jung** (Korea)
3. Molecular response prediction in esophageal squamous cell carcinomas: results of the EORTC/SAKK POWER project. – **Alexander Siebenhuener** (Switzerland)
4. IO tailored personalized medicine included side effects, drug holidays and maintenance. – **Markus Moehler** (Germany)
5. Oligometastatic disease: recommendations or studies ahead? – **Şuayib Yalçın** (Turkey)
6. Surveillance after “cure” ? – **Anneli Elme** (Estonia)
7. Overview of the ECOG-ACRIN Microbiome Working Group Clinical Trials. – **Mike Gibson** (USA)
8. Biomarker in advanced esophageal cancers: what do we need to know. – **Rupert Langer** (Austria)
9. Oral Abstract Presentation: Macrophage Infiltration and FoxP3 Density Predict Treatment Response and Survival in Esophageal Cancer Patients. – **Styliani Mantziari** (Switzerland)
10. Oral Abstract Presentation: Prognostic Impact of Treatment Modalities and Examined Lymph Nodes Count on Survival in T3–4 Esophageal Cancer: A Retrospective Cohort and Predictive Modeling Study from the SEER Database. – **BenBen Zhu** (China)

A click on each sign (>)
gives access to detailed information
on what is offered today by OESO
and the Stanford School of Medicine:
**The OESO-SEMPIRE Platform
for Excellence in Esophagology.**

The OESO-SEMPIRE Platform

Multi-disciplinary Expertise in Esophagology

o(es) Foundation
University of Geneva

o(es) the esophagus

19 disciplines >
UNESCO Resolution >
UNESCO Chair for distance learning >
UNESCO Chair in Digital CME >

New York Academy of Sciences >

Stanford MEDICINE | **SEMPIRE**
Stanford Esophageal Multidisciplinary
Program in Innovative Research Excellence

OESO-SEMPIRE Platform of Excellence



OESO Alliance

>
OESO Members
OESO Chapters
Universities
KOLs
Companies

Advisory Board >

NORTH AMERICA
EUROPE
SOUTH AMERICA
President
G. Triadafilopoulos (USA) >
6 Regional Officers
AFRICA
ASIA
AUSTRALIA

Training and Educational Courses
GiE - Gatherings in Esophagology >

Virtual Educational Channel >
Clinical case discussions >

Biennial Congresses >

The OESO Encyclopedia of Esophagology >

Access to second opinion >

Global Digital Educational Platform

o(es) Foundation
University of Geneva
Governing Board >

Education

Trainees

Fellows

Train the
Trainers
Σ

www.oeso.org

Day 3 Tuesday, June 16

Session 23

GERD – When Standard Therapy Fails

Tuesday, June 16, 4:00 – 5:30 pm

■ Auditorium Richelieu

Chairs: **Walter W. Chan (USA)** – **C. Prakash Gyawali (USA)**

1. When do PPI fail and when should PCAB be considered in treating reflux symptoms? – **Enrique Coss-Adame (Mexico)**
2. How should reflux symptoms refractory to PPI be evaluated? – **Justin Wu (Hong Kong, China)**
3. What other primary or adjunctive non-surgical options are useful for reflux symptoms? – **Mark Fox (Switzerland)**
4. What are the causes of failed fundoplication? – **Tanuja Damani (USA)**
5. How should symptomatic post-fundoplication patients be assessed? – **Salvatore Tolone (Italy)**
6. When should endoscopic anti-reflux interventions be considered? – **Kenneth Chang (USA)**

Panel Chat/Q&A

Session 24

Dynamic Imaging 2 – Functional Disorders

Tuesday June 16, 4:00 – 5:30 pm

■ Auditorium Condé

Chairs: **Nathalie Rommel (Belgium)** – **Jacqueline Allen (New Zealand)**

1. Does videomanometry cover Deglutology and Esophagology in one test? – **Nathalie Rommel (Belgium)**
2. What are the strengths of dynamic radiology in evaluation of esophageal motility disorders? – **Peter Pokieser (Austria)**
3. Neurogastrology in multilevel dysphagia of Morbus Parkinson: can videofluoroscopy contribute for the clinical work up? – **Peter Pokieser (Austria)**
4. Dynamic Radiology in Reflux disease: the surgical demands. – **Johannes Zacherl (Austria)**
5. Late postoperative complications after reflux surgery: what is the current role of dynamic radiology? – **Peter Pokieser (Austria)**
6. What is the complementary role of VFFS to FEES in neurologic patients? – **Jacqueline Allen (New Zealand)**

Panel Chat/Q&A

The Gala Evening Program
Tuesday, June 16 – 7:30 pm

The *Gala* *Evening*





at the Grand Royal Stables
of the Palace of Versailles.
Dressage performance by the
Equestrian Academy of Versailles.

Awarding of the T.O.P.
(*Transdisciplinary Oesophagology Progress*) **trophy.**

Grande Écurie du
Château de Versailles
1 Avenue Rockefeller,
Versailles



DAY 4

Wednesday, June 17

Program

Day 4 Wednesday, June 17

Session 25

Esophageal Motility Disorders: Controversies and Challenges (this or that)

Wednesday, June 17, 9:00 – 10:30 am

■ Auditorium Lulli

Chairs: **Joshua Sloan (USA)** – **Daniela Jodorkovsky (USA)** – **Ellen M. Stein (USA)**

Discussants (*part. 1*): **Joshua Sloan (USA)** – **Jorge Luis Espinoza-Rios (Peru)**

1. When to FLIP – up-front, at the end, any time, or never? – **Anh Nguyen (USA)**
2. Advantages of barium esophagram versus FLIP for EGJ outflow obstruction. – **Kristle Lynch (USA)**
3. Achalasia subtyping: FLIP + Barium versus HREM alone. – **Alberto Barchi (Italy)**
4. Achalasia treated, recurrent– how to evaluate? – **Daniela Jodorkovsky (USA)**
5. Achalasia treated, recurrent - recut or dilate? – **Claudia Barber-Caselles (Spain)**
6. Treatment of spastic disorders in the esophagus (non-achalasia): pharmacologic versus endoscopic interventions. – **Joan Chen (USA)**

Discussants (*part. 2*): **Daniela Jodorkovsky (USA)** – **Joan Chen (USA)**

7. Only time for one provocative maneuver today – how do you choose – MRS, Rapid drink or SLR? – **Daphne Ang (Singapore)**
8. Treatment or observation for Ineffective Esophageal Motility, which is better? – **Jorge Luis Espinoza-Rios (Peru)**
9. Pre-operative testing for GERD: esophageal manometry AND imaging or is less more. – **Albis Hani (Colombia)**
10. Absent contractility and proven GERD: lifestyle modification and medical management or wrap? – **Reena Chokshi (USA)**
11. Should we care more or less about bolus clearance during HREM? – **Karthik Ravi (USA)**
12. An abnormal looking manometry that is NORMAL by Chicago 4.0 Explore or ignore. – **Luis Raúl Valdovinos García (Mexico)**

Day 4 Wednesday, June 17

Session 26

State of the Art Surgery

Wednesday, June 17, 9:00 – 10:30 am

■ Auditorium Richelieu

Chairs: **Arnulf H. Hölscher (Germany)** – **Paulo Morgagni (Italy)** – **Moustafa Elshafei (Germany)**

1. Current Art of Antireflux Surgery. – **Burkhard H.A. von Rahden (Germany)**
 2. Current Art of Surgery for Achalasia. – **Aleksandar P. Simić (Serbia)**
 3. Current Art of Surgery for Esophageal Diverticula. – **Rubens Sallum (Brazil)**
 4. Current Art of Surgery for Esophageal Squamous Cell Carcinoma. – **Simone Giacomuzzi (Italy)**
 5. Current Art of Surgery for Esophageal and Junctional Adenocarcinoma. – **Katharina Beyer (Germany)**
- Panel Chat/Q&A

Session 27

Barrett's Esophagus: Physiology & Diagnosis

Wednesday, June 17, 9:00 – 10:30 am

■ Auditorium Condé

Chairs: **Margaret Zhou (USA)** – **Emanuele Asti (Italy)** – **Kee Wook Jung (Korea)**

1. Do we know the precursor of Barrett's esophagus? – **Ines Gockel (Germany)**
2. Is intestinal metaplasia of the EGJ truly Barrett's esophagus – and does it matter? – **Maha M. Guindi (USA)**
3. What is the role of the microbiome in Barrett's esophagus & can it be a target for screening or therapy? – **Margaret Zhou (USA)**
4. Who should be screened for Barrett's esophagus? – **Kenneth Vega (USA)**
5. What is the current role for non-invasive Barrett's screening modalities? – **Prasad Iyer (USA)**
6. How should endoscopy be performed for patients with suspected or known Barrett's esophagus? – **Marcia (Mimi) Canto (USA)**
7. How should we assess risk of progression after diagnosis? – **Kerry Dunbar (USA)**
8. What is the role of endoscopic ultrasound in Barrett's esophagus & should it be mandatory? – **Eun Ji Shin (USA)**
9. How to choose between radiofrequency ablation & cryotherapy for ablation? – **Shai Friedland (USA)**
10. Should nodular Barrett's be removed with EMR or ESD? – **Daryl Ramai (USA)**
11. Should all patients with Barrett's esophagus be offered anti-reflux surgery? – **Emanuele Asti (Italy)**
12. Are there patients for whom we can recommend against future surveillance? – **Massimiliano Di Pietro (UK)**

Panel Chat/Q&A

Day 4 Wednesday, June 17

Session 28

Obesity and the Esophagus

Wednesday, June 17, 11:00 am – 12:30 pm

■ Auditorium Lulli

Chairs: **Minoa K. Jung (Switzerland)** – **Silvana Perretta (France)** – **Anthony Kalloo (USA)**


1. How does obesity impact esophageal physiology? – **Eric Sheu (USA)**
2. Should esophageal physiologic testing be routinely performed prior to bariatric intervention? – **Brent Hiramoto (USA)**
3. What are the consequences of intragastric balloons on esophageal and gastrointestinal symptoms? – **Allison Schulman (USA)**
4. Do endoscopic gastric remodeling procedures cause esophageal symptoms? – **Allison Schulman (USA)**
5. How should dysphagia following bariatric surgery be evaluated? – **Claudia Barber-Caselles (Spain)**
6. Can bariatric surgery cause achalasia and achalasia-like disorders? – **Karthik Ravi (USA)**

Panel Chat/Q&A

7. What are the mechanisms underlying excessive reflux following bariatric surgery? – **Minoa K. Jung (Switzerland)**
8. How should reflux following bariatric surgery be managed? – **Silvana Perretta (France)**
9. What is the approach to a hiatal hernia following bariatric surgery? – **Salvatore Tolone (Italy)**
10. How do weight regain and associated interventions affect esophageal symptoms? – **Ahmad Bazarbashi (Saudi Arabia)**
11. What are the esophageal and gastrointestinal side effects of GLP-1 receptor agonist use? – **Nayna Lodhia (USA)**
12. What is the impact of obesity and weight loss interventions on the risk of Barrett's esophagus and esophageal cancer? – **Nitin Ahuja (USA)**

Panel Chat/Q&A

Our global footprint across hematological malignancies and solid tumors



Our pipeline in esophageal cancer

Molecules in advanced-stage of clinical development



Tislelizumab

Anti-PD-1 | IV

1L ESCC
(+ chemotherapy)


PHASE 3

APPROVED

2L ESCC

PHASE 3

APPROVED



Zanidatamab§

Anti-HER2 | IV

1L HER2+ GEA

PHASE 3

†Approved indicates approval status by the European Commission. Kindly consult your local Summary of Product Characteristics (SmPC) for the approval status of tislelizumab (TEVIMBRA®) within your region/country¹

Molecules in early-stage of clinical development

MTA Coop. PRMT5i

HPK1i

FGFR2b ADC

CEA ADC

GPC3 x 4-1BB BsAb

Legend:

Small molecule

ADC

BsAb

Safety and efficacy have not been established for investigational products and/or uses.

†Includes investigator-initiated trials; §Zymeworks/Jazz collaboration; BeOne has development and commercialization rights in APAC/ex Japan, Australia and New Zealand. 1. European Medicines Agency. Tevimbra 100 mg concentrate for solution for infusion. Summary of product characteristics. Last update: November 2025. https://www.ema.europa.eu/en/documents/product-information/tevimbra-epar-product-information_en.pdf

The region includes: North America, South America, EMEA, South East Asia, China, South Korea, Australia and New Zealand.
Abbreviations: 1L, first-line; 2L, second-line; 4-1BB, Also known as CD137/TNFSF9 = Tumor necrosis factor ligand superfamily member 9; ADC, antibody drug conjugate; APAC, Asia-Pacific; BsAb, bispecific antibody; CEA, carcinoembryonic antigen; EMEA, Europe, the Middle East and Africa; ESCC, esophageal squamous cell carcinoma; FGFR2b, fibroblast growth factor receptor 2b; GEA, gastroesophageal adenocarcinoma; GPC3, glypican-3; HER2, human epidermal growth factor receptor 2; HPK1, hematopoietic progenitor kinase 1 inhibitor; IV, intravenous; MTA Coop. PRMT5i, methylthioadenosine cooperative protein arginine methyltransferase 5 inhibitor; PD-1, programmed cell death protein 1.

© BeOne Medicines I GmbH, 2026. All Rights Reserved. Date of preparation: May 2026 | 0426-BGB-A317-MRC-036

Day 4 Wednesday, June 17

Session 29

Barrett's Esophagus: Management

Wednesday, June 17, 11:00 am – 12:30 pm

■ Auditorium Richelieu

Chairs: **Prasad Iyer (USA)** – **Marcia (Mimi) Canto (USA)**

1. How should patients with established Barrett's esophagus be followed? – **Kerry Dunbar (USA)**
 2. Is long-term surveillance necessary for low-risk patients? – **Jason Samarasena (USA)**
 3. Should all patients with dysplasia undergo ablation? – **Shai Friedland (USA)**
 4. How should Barrett's esophagus with nodularity be treated? – **Massimiliano Di Pietro (UK)**
 5. How should patients be followed after endoscopic ablation? – **Margaret Zhou (USA)**
 6. Will artificial intelligence change the management of Barrett's esophagus? – **Chamil Codipilly (USA)**
- Panel Chat/Q&A

Session 30

Esophageal Pathology – Key Controversies and Updates

Wednesday, June 17, 11:00 am – 12:30 pm

■ Auditorium Condé

Chairs: **Dhanpat Jain (USA)** – **Rupert Langer (Austria)**

1. Are the histologic features of ICI induced esophagitis specific? – **Celia Marginean (USA)**
2. What are the challenges with PDL1 scoring (CPS/TAP) for esophageal carcinoma? – **Cathy Streutker (Canada)**
3. What are the challenges of margins evaluation for dysplasia carcinoma in ESD for esophageal neoplasia: Does it even matter? – **Mikhail Lisovsky (USA)**
4. Is there a need to count Eosinophils in biopsies during follow-up of EOE biopsies during follow-up of EOE? – **Suntrea Hammer (USA)**
5. Is there any role in sub-typing BE dysplasia: Intestinal vs. foveolar? – **Dhanpat Jain (USA)**
6. What is the significance of epidermoid metaplasia in the esophagus? – **Xuchen Zhang (USA)**
7. What are the challenges of evaluation and reporting of p53 in BE for dysplasia? – **Ilke Nalbantoglu (USA)**
8. What are the advantages and disadvantages of various systems for evaluating post-therapy tumor regression? – **Rupert Langer (Austria)**
9. Current role of digital pathology and AI in esophageal carcinoma and treatment response? – **Bastian Dislich (Switzerland)**
10. Updates on WHO classification 6th edition and staging of esophageal carcinoma? – **Deyali Chatterjee (USA)**
11. What are current and upcoming biomarkers for esophageal carcinomas? – **Bella Liu (USA)**

Day 4 Wednesday, June 17

Session 31

GERD: Nuts and Bolts

Wednesday, June 17, 2:00 – 3:30 pm

■ Auditorium Lulli

Chairs: **Mark Fox (Switzerland)** – **Kerry Dunbar (USA)**

1. How should the optimal reflux monitoring modality and protocol be selected for different reflux presentations? – **Daniela Jodorkovsky (USA)**
2. Can patients with AET <4% off PPI have actionable GERD? – **Wei-Yi (Ray) Lei (Taiwan)**
3. How should reflux-symptom association data on reflux monitoring tests be used for planning symptom management? – **Kenneth Vega (USA)**
4. What is the optimal management for reflux hypersensitivity. – **Neha Patel (USA)**
5. The AET is 4-6% off PPI – now what? – **Nicola De Bortoli (Italy)**
6. Can total reflux episode count on impedance monitoring direct management? – **Benjamin Rogers (USA)**
Panel Chat/Q&A
7. What methods are available for clinical measurement of esophageal mucosal integrity? – **Rishi Naik (USA)**
8. What are the roles of mucosal impedance metrics in evaluating typical and atypical reflux symptoms? – **Adriana Lazarescu (Canada)**
9. Are there roles for barium esophagram and high-resolution manometry in GERD evaluation? – **Stefano Siboni (Italy)**
10. How can FLIP be utilized for GERD diagnosis and management? – **Abraham Khan (USA)**
11. What is the role of the brain-esophageal axis in reflux complications and extraesophageal symptoms? – **Ming-Wun Wong (Taiwan)**
12. How can reflux management protect the lungs in pre- and post-transplant patients? – **Wai-Kit Lo (USA)**
Panel Chat/Q&A

Day 4 Wednesday, June 17



Session 32

Challenging Cases in Surgery

Wednesday, June 17, 2:00 am – 3:30 pm

■ Auditorium Richelieu

Chairs: **Medhat Fanous (USA)** – **Dagmar Kollmann (Austria)**

1. No TIF where you live? A similar anti-reflux wrap can be performed laparoscopically. – **Medhat Fanous (USA)**
2. Single stage definitive surgical repair of an aorto-esophageal fistula. – **Adam Zeyara (Sweden)**
3. Visualization of the antireflux wrap using Navicam technology in an awake patient. – **Yaniv Cozacov (USA)**
4. Surgical approach to post-fundoplication outflow obstruction. – **Renato Soares (Brazil)**
5. Antesternal, subcutaneous gastric pullup for necrosis after esophagectomy. – **Yves Borbely (Switzerland)**
6. Re-operative para-conduit hernia repair after esophagectomy. – **Ealaf Shemmeri (USA)**
7. Minimally invasive resection of a GIST of the gastroesophageal junction. – **Stella Mantziari (Switzerland)**
8. When experts say "I Don't Know": A post esophagectomy paraesophageal hernia with intrathoracic bowel obstruction. – **Phillip Woodworth (USA)**
9. Pericardial tracheoplasty with or without esophagectomy for chronic foreign-body induced tracheoesophageal fistula. – **Russell E. White (Kenya)**
10. Dysphagia because of a localized mass – how to proceed? – **Dagmar Kollmann (Austria)**

Day 4 Wednesday, June 17

Session 33

Challenging cases in Oncology

Wednesday, June 17, 2:00 – 3:30 pm

■ Auditorium Condé

Chairs: **Manfred Lutz (Germany)** – **Ines Gockel (Switzerland)** – **Sara Lonardi (Italy)** – **Jean-Philippe Metges (France)**

1. HER2-Targeted Therapies: new upcoming trials. – **Alberto Puccini (Italy)**
2. Role of Immunotherapy for long-term survivorship. – **Markus Moehler (Germany)**
3. Claudin 18.2 Therapies for Gastroesophageal Cancer: full remission possible? – **Jean-Philippe Metges (France)**
4. Thinking out of the box with localized disease or TNT. – **Ines Gockel (Switzerland)**
5. CtDNA guidance? PLAGAST and more. – **Catherine Streutker (Canada)**
6. When de-escalation after first line? – **Sara Lonardi (Italy)**
7. Liver limited disease: resect metastases like in colon cancer? – **Beat Müller (Switzerland)**
8. Oral Abstract Presentation: Comparative Outcomes of Neoadjuvant Immunochemotherapy Versus Neoadjuvant Chemoradiotherapy in Locally Advanced Esophageal Cancer: A Real-World Study. – **Zhiyu Li (China)**
9. Oral Abstract Presentation: Envafolelimab plus chemotherapy as neoadjuvant therapy for resectable esophageal squamous cell carcinoma (ESCC): A prospective, single-arm, phase II study. – **Yuquan Bai (China)**
10. Final discussion: Next challenges in esophageal cancer: **ALL participants**

Day 4 Wednesday, June 17

Closing of the Congress

Wednesday, June 17, 3:30 – 5:00 pm

■ Auditorium Richelieu

Peter Grimminger (Germany)

Ellen M. Stein (USA)

Dhanpat Jain (USA)

Robert Giuli (France)





Social Program

Sunday, starting at 2:00 pm,

you can get a first glimpse of the splendor of Versailles with

Les Grandes Eaux Musicales

The musical fountains show in the palace grounds.

A guide will accompany you there from the Palais des Congrès.

Entrance points: Cour des Princes, Petite Venise, Ménagerie, Grille de Neptune, or Grille du Dragon

You can enjoy the extraordinary beauty of the Gardens of the Palace of Versailles, exploring the groves that are exceptionally open to the public, discovering the fountains in full flow, and listening to the music that once brought them to life over 350 years ago. The 55 fountains and basins, with their 600 water features, set in motion using a lyre key by the master fountain-makers of the Palace of Versailles, will delight you.

The greatest Baroque composers, from Lully to Handel, will accompany you on your royal stroll set to music.



La Salle du Jeu de Paume

Place of birth of French democracy

The Royal Tennis Court


This room has gone down in French history for the oath sworn there on June 20, 1789, by the deputies of the Third Estate, which came to be known as the Tennis Court Oath.



The Tennis Court Oath took place on June 20, 1789, in the Jeu de Paume hall at Palace of Versailles. The building had originally been constructed in 1686 for Jeu de Paume, a sport considered the ancestor of modern tennis. At that time, France was facing a major political crisis. King Louis XVI tried to stop the deputies of the Third Estate from meeting after they had declared themselves the National Assembly. Their normal meeting hall was closed by the king, officially because of renovation work.

Unable to enter, the deputies searched for another place to continue their meeting and gathered in the Jeu de Paume hall. There, led by Jean-Sylvain Bailly, they took a historic oath: they promised not to separate until France had a constitution. This moment became one of the most important symbols of the beginning of the French Revolution. The scene was later immortalized in the famous unfinished painting The Tennis Court Oath by Jacques-Louis David. Today, the hall is preserved as a museum dedicated to the history of the Revolution.

The Jeu de Paume Hall was abandoned during the Second Empire, before being converted by the Republicans into a museum of the French Revolution in 1883, to mark the centennial of the Revolution.



La Galerie des Carrosses *The Carriage Gallery*

Behind the walls of the Grand Stables at the Palace of Versailles lies one of Europe's most impressive collections: the Carriage Gallery, a veritable showcase of splendor dedicated to the vehicles of the greatest moments in French history.



Here, each carriage is much more than a means of transportation: it is a complete work of art, born of the expertise of the greatest artists and craftsmen of their time. Carved, gilded, painted, and embroidered with exceptional meticulousness, these masterpieces of wood and bronze evoke the magnificence of the ceremonies of the Ancien Régime, the Empire, and the Restoration.

Spanning nearly 1,000 square meters, the tour transports you to the heart of French dynastic history: admire the sumptuous gala sedan chair from Napoleon I's wedding, the coronation carriage of Charles X, the imposing and solemn funeral carriage of Louis XVIII, or the elegant carriages of Marie Antoinette's children, the magical sleighs, and the 18th-century sedan chairs.

This collection also showcases the technological innovations of the era in terms of drivetrains, suspensions, and comfort. From the earliest coupes to convertible carriages, these vehicles also tell a story of ingenuity.

Imagine the procession: some forty richly decorated cars, moving at a snail's pace, flanked by horses in full tack, crossing the city to the cheers of the people. All at a speed of 3 km/h, amid a symphony of clattering hooves and the clamour of the awestruck crowd.



Grande Écurie du
Château de Versailles
1 Avenue Rockefeller,
Versailles



Opportunity to stroll in the Palace gardens Monday, June 15



In the evening:
“Guided walking tour”
through the city of Versailles
en Fête as part of
the “Molière Month”.






*Bienvenue
à Versailles!*

Mois Molière

A festival which takes place all over Versailles, for everyone!

This year, Molière Month celebrates its 30th anniversary
Molière Month features 30 days, over 300 performances – most of them free – across 65 spots spread throughout the city’s neighborhoods, and 100,000 spectators.



Every June since 1996, Versailles has been doing something a little crazy: it opens its courtyards, gardens, squares, and stables to the theater.

The original idea of François de Mazières, the Mayor of Versailles who founded the festival in 1996, was simple: to bring theater to every corner of Versailles, for everyone, and free of charge. Thirty years later, that's still the case.

It is a theater and music festival that also makes forays into dance and circus arts, yet it has retained its original identity.

Performances take over the Grandes Écuries, the Théâtre Montansier, the Potager du Roi, the City Hall, chapels, and squares.

No neighborhood is left out—and the majority of the program remains free, funded by the city.

Molière Month celebrates both the great works of the classical repertoire and contemporary productions. It remains true to Molière's spirit by consistently giving theater companies a prominent place. True also to the goal of cultural democratization inherent in French cultural policy, it brings free or very affordable performances to every neighborhood in the city.

30 years of theater and music in Versailles!

During your stay, you'll surely find a moment to stroll through the town, and get the festive spirit of the once a year Mois Molière!

Information available
at the Congress Center.

Accompanying Person Program Tuesday, June 16 - 1:30 - 3:00 pm

*Step off the beaten path and discover a secret side of Versailles,
on this enchanting morning private tour of*

Marie-Antoinette's

private palace, explore the elegant Petit Trianon and beyond...





Step off the beaten path and discover a secret side of Versailles on this enchanting morning tour of Marie Antoinette’s private estate. Nestled deep within the palace gardens, the Queen’s Domain feels a world away from the grandeur of the main château.

Explore the elegant Petit Trianon, Marie Antoinette’s personal retreat, and stroll through lush gardens to her charming Normandy-style hamlet – complete with a vineyard, dairy, and vegetable farm. Designed as a rustic escape from royal life, this hidden gem offers a rare and intimate glimpse into the private world of France’s most famous queen.

A guide will accompany you there from the Palais des Congrès.

Entrance points: Estate of Trianon, Palace of Versailles,
Place d'Armes, Versailles Place d'Armes

Registration fees

Registration

A. Registration fees – Scientific program

Attendee (VAT included)	Early bird Ending January 4, 26	Standard Ending June 13, 26	On site From June 14, 26
Regular registration	EUR 780	EUR 880	EUR 950
OESO Member (<i>up-to-date</i>)	EUR 550	EUR 750	EUR 800
Fellow*	EUR 500	EUR 600	EUR 600
Speaker	EUR 599	EUR 599	EUR 599
Exhibitor	<i>(included in the sponsorship packages)</i>		
Additional exhibitor	EUR 400	EUR 400	EUR 400
Representative non sponsor Industry	EUR 1,200	EUR 1,200	EUR 1,200
Group (<i>15 delegates – 16th free</i>)	EUR 650	EUR 650	EUR 650
Accompanying person	EUR 150	EUR 150	EUR 150

B. Congress dinner (VAT included)

Attendee	EUR 150
Accompanying person	EUR 150
Sponsor (<i>over number specified in package</i>)	EUR 150

Registration fee on site includes:

- Attendance at scientific sessions
- Opening Ceremony (Sunday, June 14 – 5:30 pm)
- Welcoming reception following the Opening Ceremony
- Lunches and refreshments during breaks on June 15, 16 and 17

* Are considered as «Fellows» those who are enrolled in an accredited fellowship program and will finish their training before July 1, 2028.
The fellows who fulfil the above requirement qualify for a reduced registration fee. (Certificate may be requested during the registration process).

C. Dynamic Imaging: Case training for multi-level dysphagia "Deglutology meets Esophagology"

OESO offers tickets for three live sessions on "Deglutology meets Esophagology". Videofluoroscopy can investigate the oropharyngeal and the esophageal phase with a single investigation. More information	EUR 90
--	--------

Payment

Payment must be made in Euros (€) to Hopscotch Congrès and remitted as follows.

Terms of payment

Credit card payments and bank transfers are accepted; debit card payments are not accepted. Bank charges may be applied and are your responsibility. Payment for your registration must be made within 14 days of registration to validate your registration.

Cancellation Policy

All cancellation requests must be made in writing to the congress secretariat. For cancellations requested before March 14, the registration and social event fees will be refunded with a deduction of 50 euros for cancellation fees. After this date, no cancellation requests will be accepted (no refund of registration and social event fees).

If for reasons beyond the control of the organizers the congress has to be cancelled, the registration fee will be refunded up to the amount of funds available

Letter of Invitation

In the event that you need a letter of invitation for your visa application, you can request one when you register. Please fill out the registration form and write to the congress secretariat to indicate your request.

Visas

People requiring a visa to come to France should apply to the French Consulate in their country of origin. Details of addresses can be found on the website of the French Ministry for Foreign Affairs.

Group registration

You wish to register a group or you need a quote; you can contact the congress secretariat.

Confirmation

An official confirmation of registration will be e-mailed to the participant upon receipt of registration fees. Please remember to bring your proof of payment for presentation upon request.

It is your personal responsibility that all details such as address, booked events, number of tickets, hotel reservation, date of arrival and departure, etc. are in accordance with your wishes. We therefore strongly recommend that you read and check the letter of confirmation of registration carefully to avoid errors. In the event of any errors in the confirmed, please contact the congress secretariat.

Registration support

For any request, please send an email to: congres@hopscotchcongres.com

Conference venue: Palais des Congrès



Main Entrance

Versailles Palais des Congrès
10 Rue de la Chancellerie
78000 Versailles (France)

Reception desk Ground Floor




Auditorium Richelieu +1st Floor

Floor Plans: Palais des Congrès – Versailles


-1 Level




Ground Floor



+1st Floor



+2nd Floor



Mazarin hall – Exhibition area – Networking lunch area
Ground Floor



Click right [here](#) for a virtual tour of the Palais des Congrès

(About Versailles

The essentials

A worldwide wellknown city located 30 minutes away from Paris. Versailles, also called the Royal City, offers a wide range of attraction: touristic sites, restaurants, accomodations, shopping areas... Versailles boasts one of the finest architectural heritage in France. City of History, Versailles is also a city of life-style à la française. You will find numerous quality shops and the finests markets in the Paris region.

Versailles is of course famous for several treasures, cherished by tourists and French people: the Versailles Domaine, Jeu de Paume room, Saint-Louis Carrés, Court of Scents ...

Unusual places

Versailles is a classic historical city which also hosts unsuals buldings: the pedestrian passages, the Notre Dame market or also the Lambinet Museum. All those venues give another look at the former French Capital.

Green places

The city is proud to be one of the greenest city in the Paris region, with almost half of the terrirory dedicated to park and garden areas. Besides the castle's exquisite gardens, you can enjoy the Arboretum of Chevre-loup, the Pièce d'Eau des Suisses (over 13 hectares) or the Balbi Park.



Opening hours of the Château de Versailles:

Palace: Tuesday to Sunday, 9:00 am – 6:30 pm (last entry at 6:00 pm)


Gardens: Open daily, 8:00 am – 8:30 pm

Trianon Estate: Tuesday to Sunday, 12:00 pm – 6:30 pm (last entry at 6:00 pm)

Please note that the Palace and Trianon are closed on Mondays.

For more information, please visit: en.chateauversailles.fr/plan-your-visit/practical-information

Get to Versailles



From Paris to Versailles by public transport – 2€50 fare

Versailles is well served by public transport from Paris.

- From central Paris RER line C to Versailles Château-Rive Gauche – 5min walk to the Congress Centre
- From Paris Montparnasse Train Station to Versailles Chantiers – 20min walk to the Congress Centre
- From Paris Saint-Lazare Train Station to Versailles Rive-Droite – 15min walk to the Congress Centre



From Paris – Charles-de-Gaulle Airport – 13€ fare – 1h28

- RER B direction Saint-Rémy-lès-Chevreuse to Saint-Michel – Notre-Dame station
- RER C from Saint-Michel – Notre-Dame station direction and to Versailles Château – Rive Gauche

From Paris – Orly Airport – 13€ FARE – 1h21

- Metro 14 direction Saint-Denis - Pleyel to Bibliothèque François Mitterrand station
- From Bibliothèque François Mitterrand, RER C direction and to Versailles Château-Rive Gauche

(Thank you to our Sponsors and Exhibitors

GOLD SPONSOR



Cinclus Pharma is a late-stage clinical pharmaceutical company focused on developing innovative treatments for acid related gastrointestinal diseases. Our new PCAB, linaprazan glurate, is currently in Phase 3 development for erosive gastroesophageal reflux disease (GERD), aiming to address significant unmet medical needs in healing and symptom control.

SILVER SPONSORS



We are a global, science-led, patient-focused pharmaceutical business. We are committed to excellence in the research, development and commercialisation of prescription medicines. We aim to transform the lives of patients with improved outcomes and a better quality of life.

www.astrazeneca.com/our-company

Join our esteemed faculty at our industry satellite symposium titled:
Navigating gastroesophageal cancer care: a case-based discussion

Monday, June 15, 12:45 – 13:45 CEST

Lulli Room – Versailles Palais des Congrès, Versailles, France Veeva ID: FR-25863



Since its establishment in 1984, HK inno.N has gained competitiveness in the businesses of prescription drugs, active pharmaceutical ingredients, health supplements and beauty products. Drawing on the company's experience and knowhow in developing novel drugs, HK inno.N succeeded in launching 'K-CAB', the 30th novel drug to be developed and registered in Korea, to great acclaim. Building on this success, HK inno.N remains committed to growing into a global bio health company built on outstanding products and technologies that bring us closer to a healthier future. www.inno-n.com/eng



leo-pharma.com



MIMEDX is a transformational placental biologics company, developing and distributing placental tissue allografts with patent-protected, proprietary processes for multiple sectors of healthcare. As a pioneer in placental tissue engineering, we have both a commercial business, focused on addressing the needs of patients with acute and chronic non-healing wounds, and a promising late-stage pipeline targeted at decreasing pain and improving function for patients with degenerative musculoskeletal conditions. For additional information, please visit www.mimedx.com



At MSD France, the French subsidiary of Merck & Co., Inc., Rahway, New Jersey, we are united by a common goal: harnessing the power of science to save and improve lives. For more than 130 years, MSD has been developing important medicines and vaccines that bring hope to society. We aspire to be the world's leading research-intensive biopharmaceutical company, particularly in the fields of oncology, vaccines, and infectious diseases. Today, we are at the forefront of research, providing healthcare professionals and patients with innovative healthcare solutions and advancing the prevention and treatment of diseases. We foster a culture of diversity and inclusion and act responsibly every day to help create a safe, sustainable, and healthier future for all. For more information, please visit www.msd-france.com and follow us on [LinkedIn](#) and [YouTube](#).

PARTNERS



BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The Company has a growing global team spanning six continents who are driven by scientific excellence and exceptional speed to reach more patients than ever before. To learn more about BeOne, please visit www.beonemedicines.com and follow us on [LinkedIn](#), [X](#), [Facebook](#) and [Instagram](#).



[Enterra Medical](#) is a medical technology company dedicated to improving the lives of patients suffering from gastroparesis, a chronic digestive disorder. Formed in 2022, the company focuses on advancing innovative healthcare solutions through Enterra Therapy, the first fully implantable gastric electrical stimulation system designed to reduce severe nausea and vomiting symptoms. Through technological innovation, clinical research, and expanded access to treatment, Enterra Medical aims to help patients regain a better quality of life.



Laborie is a global medical technology company specializing in Gastroenterology, Urology & Urogynecology, and Obstetrics, Gynecology & Neonatal. We believe that great healthcare is an essential safeguard of human dignity. We have a wide variety of gastrointestinal diagnostic devices. The Ohmega, a small, lightweight recorder for pH-Impedance measurement to diagnose GERD. The Solar GI HRM/HRIM/HRAM systems have revolutionary Quick-View software with the new London Protocol and Chicago classification. The Hydrogenius & Gastrogenius are breath monitors for measurement of hydrogen and combined methane, hydrogen and oxygen.



Nordic Pharma is a European specialty pharmaceutical company committed to addressing unmet medical needs through focused expertise and close collaboration with healthcare professionals. In oncology, Nordic Pharma supports the use of Taysuno® (tegafur/gimeracil/oteracil), an oral fluoropyrimidine available across Europe for the treatment of advanced gastric cancer and metastatic Colorectal Cancer. Through ongoing scientific exchange and medical education, Nordic Pharma aims to support the optimal management of patients receiving fluoropyrimidine based therapy. www.nordicpharma.ch/en



www.phathompharma.com



Since 2007, Regeneron and Sanofi have collaborated to help people with debilitating and complex conditions that are often difficult to diagnose and treat, using innovative technology platforms. Regeneron is a leading science-based biopharmaceutical company that invents, develops and commercializes medicines to treat serious medical conditions. Sanofi is an innovative global healthcare company that provides potentially life-changing treatment options and life-saving vaccine protection to millions of people globally. For more information, please visit www.Regeneron.com and www.Sanofi.com.

Conference Speakers

S = Session | CS = Chair | MS = Moderators |
 DS = Discussant | OC = Opening Ceremony
 CPS = Chair Poster Session |
 MC = Motility course | CMC = Chair Motility
 course | PMC = Presenter Motility course |
 DMC = Discussant Motility course

- Nitin Ahuja (USA) – S28
- Jacqueline Allen (New Zealand) – S7 – DS7 – CS24 – S24
- Thierry André (France) – S1
- Daphne Ang (Singapore) – S25
- Emanuele Asti (Italy) – S19 – CS27 – S27
- Yuquan Bai (China) – S33
- Chang Seok Bang (Korea) – S9
- Claudia Barber-Caselles (Spain) – S25 – S28
- Alberto Barchi (Italy) – S25
- Anastasia Bartashova – DS16
- Rahul Bharadwaj (OESO, Malaysia) – S10
- Ahmad Najdat Bazarbashi (Saudi Arabia) – S6 – S28
- Reginald Bell (USA) – S19
- Irit Ben-Aharon (Israel) – S1
- Frank Benedix (Germany) – S14
- Felix Berlth (Germany) – S8 – S17
- Katharina Beyer (Germany) – S26
- Claire Beveridge (USA) – S12 – S20
- Jonathan Bock (USA) – DS7
- Serhat Bor (Turkey) – DS7 – S13
- Yves Borbely (Switzerland) – S15 – S32
- So Young Byun (Korea) – S3 – S4
- Marcia (Mimi) Canto (USA) – S19 – S27 – CS29
- Thomas L. Carroll (USA) – S7 – DS7
- Walter W. Chan (USA) – OC – CMC – DMC – CS2 – DS7 – S13 – S18 – CS20 – CS23 – CPS
- Kenneth Chang (USA) – S19 – S23
- Deyali Chatterjee (USA) – S30
- Chien-Lin (Harry) Chen (Taiwan) – S2
- Joan Chen (USA) – DS25 – S25
- Judy Chen (USA) – S15
- Mickael Chevally (Switzerland) – S14
- Philip Chiu (Hong Kong) – CS6 – S6 – S10 – DS19
- Yu Kyung Cho (Korea) – S18
- Reena Chokshi (USA) – S25
- Cheol Woong Choi (Korea) – S6
- Seung-Hun (Daniel) Chon (Germany) – S9
- John O. Clarke (USA) – OC – DMC – S12 – CS20
- Chamil Codipilly (USA) – S29
- Yaniv Cozacov (USA) – S32
- Enrique Coss-Adame (Mexico) – S23
- Tanuja Damani (USA) – S11 – S23
- Nicola de Bortoli (Italy) – S13 – S31
- Hiroyuki Daiko (Japan) – S8
- Christelle De la Fouchardière (France) – CS1 – S1 – CS33
- Jonathan Delong (USA) – S16 – DS16
- Giovanni De Manzoni (Italy) – CS14 – S14
- Massimiliano Di Pietro (UK) – S27 – S29
- Bastian Dislich (Switzerland) – S30
- Yanhua Duan (China) – S3
- Kerry Dunbar (USA) – CS18 – S27 – S29 – CS31
- Anneli Elme – CS22 – S22
- Moustafa Elshafai (Germany) – CS26
- Jorge Luis Espinoza Rios (Peru) – DS25 – S25
- Vincent Wentao Fang (China) – CS17
- Medhat Fanous (USA) – S19 – CS32 – S32
- Ronnie Fass (USA) – S5 – S13
- Jonas Feilchenfeldt (Switzerland) – S22
- Valter N. Felix (Brazil) – S19
- Filippo Filicori (USA) – S16 – DS16
- Mark Fox (Switzerland) – S13 – S23 – CS31
- Shai Friedland (USA) – S6 – S27 – S29
- Sravanya Gavini (USA) – MC – PMC
- Gaurav Ghosh (USA) – MC – PMC
- Simone Giacomuzzi (Italy) – S8 – S26
- Mike Gibson (USA) – S1 – S3 – CS22 – S22
- Suzanne Gisbertz (The Netherlands) – S10
- Robert Giuli (France) – OC – S10
- Ines Gockel (Switzerland) – S10 – S17 – S27 – CS33 – S33
- Nirmala Gonsalves (USA) – CS12 – S13 – S20
- Peter Grimminger (Germany) – S8 – CS11 – CS17
- Livia Guadagnoli (USA) – S2
- Maha M. Guindi (USA) – S16 – S27
- Christian Gutschow (Switzerland) – S14
- C. Prakash Gyawali (USA) – OC – CMC – DMC – CS2 – CS5 – CS13 – S13 – S18 – CS23
- Suntrea Hammer (USA) – S30
- Albis Hani (Colombia) – DS18 – S25
- David Hartnett (USA) – S4
- Joo Ha Hwang (USA) – S6
- Brent Hiramoto (USA) – S28
- Arnulf H. Hölscher (Germany) – OC – CS14 – CS26

S = Session | CS = Chair | MS = Moderators | DS = Discussant | OC = Opening Ceremony | CPS = Chair Poster Session
MC = Motility course | CMC = Chair Motility course | PMC = Presenter Motility course | DMC = Discussant Motility course

- Toshitaka Hoppo (USA) – **S6 – CS19**
- Jennifer Horsley-Silva (USA) – **DS12 – S12**
- Po-Kuei Hsu (Taiwan) – **S4**
- Joo Ha Hwang (USA) – **CS6 – S9**
- Prasad Iyer (USA) – **S27 – CS29**
- Gretchen Purcell Jackson (USA) – **CS16 – S16 – MS16**
- Dhanpat Jain (USA) – **S10 – CS30 – S30**
- Yan Jiang (USA) – **MC – PMC**
- Daniela Jodorkovsky (USA) – **CS25 – S25 – S31**
- Nikki Johnston (USA) – **OC – CS3 – CS7 – S7 – S10 – S13**
- Moon Kyung Joo (Korea) – **S6**
- Kee Wook Jung (Korea) – **S18 – CS27**
- Da Hyun Jung (Korea) – **S9**
- Hwoon-Yong Jung (Korea) – **CS9 – S22**
- Minoa K. Jung (Switzerland) – **CS28 – S28**
- Allon Kahn (USA) – **S15**
- Anthony Kalloo (USA) – **S6 – CS28**
- Hanoch Kashtan (Israel) – **S1**
- Priya Kathpalia (USA) – **MC – PMC**
- Kourtney L. Kemp (USA) – **S15**
- Abraham Khan (USA) – **S31**
- Mouen Khashab (USA) – **CS6 – S6 – S9**
- Byung-Wook Kim (Korea) – **CS6 – CS9**
- Do Hoon Kim (Korea) – **S18**
- Jennifer Klasen (Switzerland) – **S11**
- Dagmar Kollmann (Austria) – **CS32 – S32**
- Ludwig Kramer (Austria) – **S21**
- Yusef Kudsi (USA) – **CS11**
- Braden Kuo (USA) – **S5**
- Jasmina Kuvendjiska (Germany) – **S8**
- Rupert Langer (Austria) – **S16 – DS16 – S22 – CS30 – S30**
- Adriana Lazarescu (Canada) – **S31**
- Jérôme R. Lechien (Belgium) – **S7 – DS7 – S10**
- Ju Yup Lee (Korea) – **S18**
- Sang Kil Lee (Korea) – **CS18**
- Wei-Yi (Ray) Lei (Taiwan) – **S31**
- Johannes Lenglinger (Switzerland) – **S15**
- Zhiyu Li (China) – **S33**
- Bella Liu (USA) – **S30**
- Mikhail Lisovsky (USA) – **S30**
- Wai-Kit Lo (USA) – **S31**
- Nayna Lodhia (USA) – **S28**
- Sara Lonardi (Italy) – **CS33– S33**
- Vladimir Lozanovski (Germany) – **S4**
- Karolina Lungova (USA) – **S3**
- Manfred Lutz (Germany) – **CS1 – S1– CS22 – CS33**
- Kristle Lynch (USA) – **S25**
- Pavan Mallur (USA) – **S7**
- Stella Mantziari (France) – **S32**
- Styliani Mantziari (Switzerland) – **S22**
- Celia Marginean (USA) – **S30**
- Tomoaki Matsumura (Japan) – **S6**
- Emily McGowan (USA) – **DS12 – S12 – S20**
- Calies Menard-Katcher (USA) – **S12**
- Paul Menard-Katcher (USA) – **MC – PMC**
- Nainika Menon (UK) – **S15**
- Helmut Messmann (Germany) – **DS6 – S6 – DS9**
- Jean-Philippe Metges (France) – **CS33 – S33**
- Markus Moehler (Germany) – **OC – CS1 – S22 – S33**
- Andrés Francisco Navarrete Molina (Chile) – **CS8 – S8**
- Stefan Mönig (Switzerland) – **OC – CS9 – CS14**
- Jacob Moremen (USA) – **S15**
- Paulo Morgagni (Italy) – **CS26**
- Mayssan Muftah (USA) – **CS3 – S4 – S12**
- Amanda Muir (USA) – **S3 – CS18 – S18 – S20**
- Beat Müller (Switzerland) – **S33**
- Rishi Naik (USA) – **S15 – S31**
- Ilke Nalbantoglu (USA) – **S30**
- Anh Nguyen (USA) – **CMC – MC – S25**
- Mark Noar (USA) – **S7 – DS7**
- Jung-Hwan Oh (Korea) – **DS18**
- Frank G. Ondrey (USA) – **S10**
- Moo In Park (Korea) – **CS18**
- Walter Park (USA) – **S9**
- Neha Patel (USA) – **S31**
- Silvana Perretta (France) – **S6 – S11 – CS28 – S28**
- Katja Petrowski (Germany) – **S1**
- Guillaume Piessen (France) – **S17**
- Peter Pokieser (Austria) – **S10 – S16 – CS21 – S21 – S24**
- Alberto Puccini (Italy) – **S33**
- Daryl Ramai (USA) – **S19 – S27**
- Derrick Randall (Canada) – **S7**
- Jari Räsänen (Finland) – **S17**
- Karthik Ravi (USA) – **S25 – S28**

S = Session | CS = Chair | MS = Moderators | DS = Discussant | OC = Opening Ceremony | CPS = Chair Poster Session
MC = Motility course | CMC = Chair Motility course | PMC = Presenter Motility course | DMC = Discussant Motility course

- William Ravich (USA) – S12 – S21
- Matthew Read (Australia) – CS8 – S10
- José María Remes Troche (Mexico) – S2 – S5 – DMC – S13
- Allyson Richardson (USA) – MC – PMC
- Megan Riehl (USA) – S2
- Benjamin Rogers (USA) – PMC – MC – CS15 – S16 – DS16 – S31
- Sabine Roman (France) – S5
- Nathalie Rommel (Belgium) – CS24 – S24
- Rubens Sallum (Brazil) – S11 – S17 – S26
- Jason Samarasena (USA) – S16 – DS16
- Tina Samuels (USA) – S7
- Santosh Sanagapali (Australia) – S2
- Inderpal (Netu) Singh Sarkaria (USA) – CS8 – S11 – S21
- Edoardo Savarino (Italy) – S5 – DS7
- Akinari Sawada (Japan) – PMC – S2
- Carmelo Scarpignato (Malta) – CS13 – S13
- Christoph Schlag (Switzerland) – S20
- Paul Schneider (Switzerland) – S14
- Tilman Schlick (Germany) – S11
- Allison R. Schulman (USA) – S28
- Guido Schumacher (Italy) – CS17
- Eric Shah (USA) – S16 – DS16
- Ealaf Shemmeri (USA) – CS4 – S32
- Eric Sheu (USA) – S28
- Eun Ji Shin (USA) – DS9 – CS19 – S27
- Sung Kwan Shin (Korea) – DS6 – DS9
- Stefano Siboni (Italy) – S4 – S7 – DS7 – S31
- Alexander Siebenhuener – S22
- Daniel Sifrim (UK) – CS5 – S13
- Aleksandar P. Simić (Serbia) – S26
- Joshua Sloan (USA) – S12 – CS25 – DS25
- Diana Snyder (USA) – MC – PMC
- Renato Soares (Brazil) – S32
- Irene Sonu (USA) – PMC – MC
- Marco Sozzi (Italy) – MC – PMC – S4
- Ellen M. Stein (USA) – CMC – DMC – S5 – S12 – S13 – CS25
- Alex Strauss (USA) – S12
- Catherine Streutker (Canada) – S30 – S33
- Lee L. Swanström (France) – CS16 – S16 – MS16 – CS19 – S19
- Flavio Takeda (Brazil) – CS11
- Roger Tatum (USA) – OC – DMC – PMC – CS15
- Eduardo Terán (Spain) – S1
- Salvatore Tolone (Italy) – S23 – S28
- Benjamin Tordjman (Canada) – S4
- Ping-Huei Tseng (Taiwan) – S15 – S19
- Luis Raúl Valdovinos García (Mexico) – S4 – S25
- Alexandra Vandenberg (USA) – S7
- Kenneth Vega (USA) – S27 – S31
- Felipe Victor (Brazil) – S11
- Pierfrancesco Visaggi (Italy) – CS4 – CS12 – S20
- Burkhard H.A. von Rahden (Germany) – S26
- Kevin Waters (USA) – S12
- Russell E. White (Kenya) – OC – S10 – S32
- Ian Wong (Hong Kong) – S17
- Marc Wong (Hong Kong) – MC – PMC
- Ming-Wun Wong (Taiwan) – S31
- Phillip Woodworth (USA) – S32
- Justin Wu (Hong Kong) – S13 – S23
- Lucjan Wyrwicz (Poland) – S1
- Şuayib Yalçın (Turkey) – S22
- Hyo-Joon Yang (Korea) – S9
- Johannes Zacherl (Austria) – S14 – CS21 – S21 – S24
- Aziz Zaanani (France) – S1
- Frank Zerbib (France) – CS7 – S10
- Adam Zeyara (Sweden) – S32
- Xuchen Zhang (USA) – S30
- Lei Zhao (USA) – S30
- Bruno Zilberstein (Brazil) – S10
- Margaret Zhou (USA) – CS27 – S27 – S29
- BenBen Zhu (China) – S3 – S22

The OESO Charter

for the members of OESO

Each of the specialists from all the 19 disciplines represented in the OESO contributed to build up this Organization which rapidly acquired its reputation of excellence in the international scientific community.

In becoming a member of OESO, I accepted to adhere to the original idea at the basis of the conception of the OESO, and to allow my personal scientific reputation to uphold this distinctive society which has steadily continued, since 1978, to successfully serve the advancement of the discipline of esophagology.

I approved the aims as defined in the Bylaws of the OESO.

As an expert in my field, I shall continue to foster the founding spirit and the aims of the OESO, and I shall strive to broaden the reach of its achievements amongst the national and international bodies to which I belong.

In general terms, as a member of OESO, I consider myself as vested with the responsibility to represent a part of what this multi-disciplinary Organization signifies, and to contribute to maintain its scientific credibility and its reputation of excellence.

www.oeso.org





www.oeso.org



ORGANIZER:

**HOPSCOTCH
CONGRÈS**

Information: asurcouf@hopscotch.one

OESO Contact

Robert Giuli, MD, FACS – Professor of Surgery
OESO – 2 Blvd Pershing – 75017 Paris / France
Phone +33 (0)1 55 37 90 15
robert.giuli@oeso.org
Michèle Liegeon – michele.liegeon@oeso.org